膵癌治療　up-to-date　2015

出版社： 医学図書出版
著者：
発行日： 2014-12-05
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784865170870
電子書籍版： 2014-12-05 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,700 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,850 円(税込)

購入する

目次

  • 膵癌治療 up-to-date 2015

    ―目次―

    1．膵癌治療の現状と将来展望
    2．膵癌の診断法
    3．膵癌補助療法の効果判定
    4．Borderline resectable膵癌の診断と手術
    5．術前補助療法の適応と効果
    6．Initially unresectable膵癌の治療
    7．放射線療法
    8．興味ある症例

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 膵癌治療の現状と将来展望

P.6 掲載の参考文献
1) 中尾昭公 : 本邦における膵臓外科の歴史と私の経験. 膵臓, 26. 117-122.
Medical*Online
2) Sato T, Saitoh Y, Noto N, et al : Follow-up studies of radical resection for pancreaticoduodenal cancer. Ann Surg 1977, 186 : 581-588.
PubMed
3) Fortner JG : Regional resection of cancer of the pancreas : a new surgical approach. Surgery 1973 ; 73 : 307-320.
PubMed
4) Farnell MB, Pearson RK, Sarr MG, et al : A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005 ; 138 : 618-628, discussion 628-630.
 
5) Nguyen TC, Sohn TA, Cameron JL, et al : Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma : a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg 2003 ; 7 : 1-9, discussion 9-11.
 
6) Pedrazzoli S, DiCarlo V, Dionigi R, et al : Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas : a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998 ; 228 : 508-517.
 
7) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012 ; 19 : 230-241.
 
8) Jang JY, Kang MJ, Heo JS, et al : A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 2014 ; 259 : 656-664.
PubMed
9) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 ; 297 : 267-277.
PubMed
10) Kimura W, Miyata H, Gotoh M, et al : A pancreaticoduodenectomy risk model derived from 8,575 cases from a national single-race population (Japanese) using a web-based data entry system : the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 2014 ; 259 : 773-780.
 
11) Yeo CJ, Cameron JL, Sohn TA, et al : Six hundred fifty consecutive pancreaticoduodenectomies in the 1990 s : pathology, complications, and outcomes. Ann Surg 1997 ; 226 : 248-257, discussion 257-260.
 
12) Cameron JL, Riall TS, Coleman J, et al : 0ne thousand consecutive pancreaticoduodenectomies. Ann Surg 2006 ; 244 : 10-15.
 
13) Are C, Afuh C, Ravipati L, et al : Preoperative nomogram to predict risk of perioperative mortality following pan-creatic resections for malignancy. J Gastrointest Surg 2009 ; 13 : 2152-2162.
 
14) Parikh P, Shiloach M, Cohen ME, et al : Pancreatectomy risk calculator : an ACS-NSQIP resource. HPB (Oxford) 2010 ; 12 : 488-497.
PubMed
15) Venkat R, Puhan MA, Schulick RD, et al : Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy : a novel scoring system. Arch Surg 2011 ; 146 : 1277-1284.
PubMed
16) Castleberry AW, White RR, De La Fuente SG, et al : The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy : an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol 2012 ; 19 : 4068-4077.
 
17) Kim CG, Jo S, Kim JS : Impact of surgical volume on nationwide hospital mortality after pancreaticoduodenectomy. World J Gastroenterol 2012 ; 18 : 4175-4181.
PubMed
18) Assifi MM, Lindenmeyer J, Leiby BE, et al : Surgical Apgar score predicts perioperative morbidity in patients undergoing pancreaticoduodenectomy at a high-volume center. J Gastrointest Surg 2012 ; 16 : 275-281.
 
P.15 掲載の参考文献
1) 独立行政法人国立がん研究センター がん対策情報センター がん情報サービス http://ganjoho.jp/professional/statistics/index.html
 
2) 日本膵臓学会 膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 2007 ; 22 : e29-32.
 
3) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
4) Conroy T, Desseigne F, Ychou M et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
5) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 ; 369 : 1691-1703.
PubMed
6) Neoptolemos JP, Dunn JA, Stocken DD, et al : Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer : a randomised controlled trial. Lancet 2001 ; 358 : 1576-1585.
PubMed
7) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 2013 ; 310 : 1473-1481.
PubMed
8) Neoptolemos JP, Moore MJ, Cox TF, et al : Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial. JAMA 2012 ; 308 : 147-156.
 
9) Uesaka K, Fukutomi A, Boku N, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study).J Clin Oncol 2012 ; 30 (suppl 34 ; abstract 145)
 
10) NCCNガイドライン 日本語版 (膵腺癌). http://www.tri-kobe.org/nccn/guideline/pancreas/japanese/pancreatic.pdf
 
11) Kato H, Usui M, Isaji S, et al : Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer : a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 Mar 14.[Epub ahead of print]
 
12) Satoi S, Yanagimoto H, Toyokawa H, et al : Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 2011 ; 40 : 426-432.
PubMed
13) Doi R, Imamura M, Hosotani R, et al : Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer : final results of a randornized multi-institutional trial. Surg Today 2008 ; 38 : 1021-1028.
PubMed
14) Ando N, Kato H, Igaki H, et al : A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chernotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).Ann Surg Oncol 2012 ; 19 : 68-74.
 
15) 日本膵臓学会 膵癌診療ガイドライン改訂委員会編,科学的根拠に基づく膵癌診療ガイドライン 2013年版.金原出版,2013 ; 83-86,92-94.
 
16) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2014 ; 21 : 148-158.
PubMed
17) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013 ; 20 : 3794-3801.
PubMed
18) 元井冬彦,力山敏樹,片寄友,ほか : 膵癌に対する術前化学療法.日消誌 2011 ; 108 : 1654-1660.
Medical*Online
19) 元井冬彦,片寄友,江川新一,ほか : 切除企図膵癌に対する術前治療戦略の意義.膵臓 2013 ; 28 : 25-33.
Medical*Online
20) 元井冬彦,川口桂,青木豪,ほか : 切除企図・切除可能膵癌に対する術前化学療法の有効性.癌と化療 2013 ; 40 : 1632-1636.
Medical*Online
21) Heinrich S, Pestalozzi B, Lesurtel M, et al : Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer : a randomized multicenter phase III study (NEOPAC study).BMC Cancer 2011 ; 11 : 346.
PubMed
22) UMIN臨床試験登録システム (UMIN-CTR) UMIN-ID : UMIN000009446 http://www.urnin.ac.jp/ctr/index-j.htm
 
P.23 掲載の参考文献
1) がん研究振興財団 : 癌の統計 '12. http://ganjoho.jp/professional/statistics/backnumber/2012_jp.html
 
2) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th Year Anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-992.
PubMed
3) Pedrazzoli S, DiCarlo V, Dionigi R, et al : Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas : amulticenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998 ; 228 : 508-517.
 
4) Nguyen TC, Sohn TA, Cameron JL, et al : Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma : a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg 2003 ; 7 : 1-9.
PubMed
5) Farnell MB, Pearson RK, Sarr MG, et al : A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005 ; 138 : 618-625.
PubMed
6) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012 ; 19 : 230-241.
 
7) Jang JY, Kang MJ, Heo JS, et al : A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 2014 ; 259 : 656-664.
PubMed
8) Uesaka K, Fukutomi A, Boku N, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2013 ; 31 suppl (2013 Gastrointestinal Cancers Symposium) : Abstr. #145.
 
9) Kalser MH, Ellenberg SS : Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985 ; 120 : 899-903.
PubMed
10) Neoptolemos JP, Stocken DD, Friess H, et al : A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 ; 350 : 1200-1210.
PubMed
11) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 ; 297 : 267-277.
PubMed
12) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA. 2013 310 : 1473-1481.
PubMed
13) Neoptolemos JP, Stocken DD, Bassi C, et al : Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial. JAMA 2010 ; 304 : 1073-1081.
PubMed
14) 上坂克彦, 福冨晃, 朴成和, ほか : 膵癌の術後補助療法の最近の進歩 : JASPAC01を中心として. 胆と膵 2013 : 34 : 625-629.
Medical*Online
15) 伊藤貴明, 上坂克彦, 杉浦禎一, ほか : 術後補助化学療法の新展開. 肝胆膵 2014 ; 68 : 895-900.
Medical*Online
16) 岡村行泰, 伊藤貴明, 杉浦禎一, ほか. 胆道癌・膵癌・膵嚢胞性腫瘍の術後化学療法・経過観察-膵癌術後補助化学療法-. 肝胆膵 2014 ; 69 : 57-61.
 
17) Maeda A, Boku N, Fukutomi A, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer : Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol 2008 ; 38 : 227-229.
 
18) 日本膵臓学会 膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013
 
19) Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-1966.
 
20) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
21) Von Hoff DD, Ramanathan RK, Borad MJ, et al : Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer : a phase I/II trial. J Clin Oncol 2011 ; 29 : 4548-4554.
 
22) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
23) Ziprin P, Ridgway PF, Pfistermuller KL, et al : ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha : a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes 2003 ; 10 : 141-154.
PubMed
24) Herrmann R, Bodoky G, Ruhstaller T, et al : Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer : a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007 ; 25 : 2212-2217.
 
25) Valle JW, Palmer D, Jackson R, et al : Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas : ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014 ; 32 : 504-512.
PubMed
26) Murata Y, Hamada T, Kishiwada M, et al : Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepatobiliary Pancreat Sci 2012 ; 19 : 413-425.
 
27) Nakagawa N, Murakami Y, Uemura K, et al : Combined analysis of intratumoral human equihbrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013 ; 153 : 565-575.
PubMed
28) Marechal R, Bachet JB, Mackey JR, et al : Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012 ; 143 : 664-674.
PubMed
29) Ichikawa W, Takahashi T, Suto K, et al : Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004 ; 91 : 1245-1250.
 
30) Kamoshida S, Suzuki M, Shimomura R, et al. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer 2007 ; 96 : 277-283.
 
31) Ishido K, Azuma M, Koizumi W, et al : Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy. Pharmacogenet Genomics 2009 ; 19 : 955-964.
 
32) Koizumi W, Tanabe S, Azuma M et al : Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer 2010 ; 126 : 162-170.
PubMed
33) Kondo N, Murakami Y, Uemura K, et al : Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. Ann Surg Oncol 2012 ; 3 ; S646-655.
 
34) Ando Y, Saka H, Ando M, et al : Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Res 2010 ; 60 : 6921-6926.
 
P.34 掲載の参考文献
1) がん情報サービス 一般向け統計情報 最新がん統計. http://ganjoho.jp/public/statistics/pub/.
 
2) Kimura W, Miyata H, Gotoh M, et al : A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system : the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 2014 ; 259 : 773-780.
PubMed
3) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th Year Anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-992.
PubMed
4) 奈良聡, 島田和明, 江崎稔, ほか : 膵癌に対する膵頭十二指腸切除後早期再発予測因子の検討 : 術後補助化学療法の限界と適切な膵癌切除症例の選択. 癌の臨床 2013 ; 59 : 53-59.
Medical*Online
5) Kosuge T, Kiuchi T, Mukai K, et al : A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006 ; 36 : 159-165.
PubMed
6) Ueno H, Kosuge T, Matsuyama Y, et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009 ; 101 : 908-915.
 
7) Ueseka K, Fukutomi A, Boku N, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2013 ; 31 : No 4_suppl (February 1 Supplement).
 
8) 日本膵臓学会 膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
9) NCCN : Guidelines in Oncology : Pancreatic Adenocarcinoma Version 2. 2014. 2014
PubMed
10) Seufferlein T, Bachet JB, Van Cutsem E, et al : Pancreatic adenocarcinoma : ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012 ; 23 Suppl 7 : vii33-40.
 
11) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 2013 ; 310 : 1473-1481.
PubMed
12) Neoptolemos JP, Stocken DD, Bassi C, et al : Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial. JAMA 2010 ; 304 : 1073-1081.
PubMed
13) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 ; 297 : 267-277.
PubMed
14) Neoptolemos JP, Stocken DD, Friess H, et al : A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 ; 350 : 1200-1210.
PubMed
15) Bakkevold KE, Arnesjo B, Dahl O, et al : Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993 ; 29 A : 698-703.
 
16) Takada T, Amano H, Yasuda H, et al : Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002 ; 95 : 1685-1695.
PubMed
17) Choti MA : Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med 2004 ; 350 : 1249-1251.
PubMed
18) Morris SL, Beasley M, Leslie M : Chemotherapy for pancreatic cancer. N Engl J Med 2004 ; 350 : 2713-2715, author reply 2713-2715.
 
19) Burris HA, 3rd Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-2413.
 
20) Sakuramoto S, Sasako M, Yamaguchi T, et al : Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357 : 1810-1820.
 
21) Yoshida M, Ishiguro M, Ikejiri K, et al : S-1 as adjuvant chemotherapy for stage III colon cancer : A randomized phase III study (ACTS-CC trial). Ann Oncol, 2014.
PubMed
22) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
23) Kalser MH, Ellenberg SS : Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985 ; 120 : 899-903.
PubMed
24) Regine WF, Winter KA, Abrams R, et al : Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma : 5-year analysis of the U. S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011 ; 18 : 1319-1326.
 
25) Regine WF, Winter KA, Abrams RA, et al : Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma : a randomized controlled trial. JAMA 2008 ; 299 : 1019-1026.
PubMed
26) Smeenk HG, van Eijck CH, Hop WC, et al : Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation : long-term results of EORTC trial 40891. Ann Surg 2007 ; 246 : 734-740.
PubMed
27) Klinkenbijl JH, Jeekel J, Sahmoud T, et al : Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region : phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999 ; 230 : 776-782, discussion 782-784.
 
28) Van Laethem JL, Hammel P, Mornex F, et al : Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer : a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010 ; 28 : 4450-4456.
PubMed
29) Schmidt J, Abel U, Debus J, et al : Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012 ; 30 : 4077-4083.
PubMed
30) Hsu CC, Herman JM, Corsini MM, et al : Adjuvant chemoradiation for pancreatic adenocarcinoma : the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010 ; 17 : 981-990.
 
31) Andriulli A, Festa V, Botteri E, et al : Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer : a meta-analysis of prospective studies. Ann Surg Oncol 2012 ; 19 : 1644-1662.
 
32) Assifi MM, Lu X, Eibl G, et al : Neoadjuvant therapy in pancreatic adenocarcinoma : a meta-analysis of phase II trials. Surgery 2011 ; 150 : 466-473.
PubMed
33) Gillen S, Schuster T, Meyer Zum BUuschenfelde C, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e1000267.
 
34) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
35) 膵癌登録委員会編, 切除例における化学療法. 膵臓 2007 ; 22 : e156-166.
 
36) Katz MH, Marsh R, Herman JM, et al : Borderline resectable pancreatic cancer : need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013 ; 20 : 2787-2795.
PubMed
37) Katz M H, Wolff R, Crane C H, et al : Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation : a phase II trial. Ann Surg Oncol 2011 ; 18 : 3615-3622.
PubMed
38) Nagrial AM, Chang DK, Nguyen NQ, et al : Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer 2014 ; 110 : 313-319.
PubMed
39) Raigani S, Ammori J, Kim J, et al : Trends in the treatment of resectable pancreatic adenocarcinoma. J Gastrointest Surg 2014 ; 18 : 113-123.
PubMed
P.44 掲載の参考文献
1) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 : 15 : 2403-2413.
 
2) Okada S, Ueno H, Okusaka T, et al : Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001 ; 31 : 7-12.
PubMed
3) Okusaka T, Funakoshi A, Furuse J, et al : Alate phase III study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008 ; 61 : 615-621.
 
4) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST Study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
5) Ueno H, Okusaka T, Furuse J, et al : Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol 2011 ; 41 : 953-958.
PubMed
6) Ishii H, Okusaka T, Ikari T, et al : Efficacy and safety of Gemcitabine plus S-1 treatment in locally advanced and metastatic pancreatic cancer : A pooled analysis of three randomized trials using updated individual patient data. The European Cancer Congress 2013. Abstr 2595.
 
7) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-1966.
 
8) Okusaka T, Furuse J, Funakoshi A, et al : Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 2011 : 102 : 425-431.
PubMed
9) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
10) Von Hoff DD, Ramanathan RK, Borad MJ, et al : Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer : a phase I/II trial. J Clin Oncol 2011 ; 29 : 4548-4554.
 
11) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 ; 369 : 1691-1703.
PubMed
12) Ulrich-Pur H, Raderer M, Verena Kornek G, et al : Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003 ; 88 : 1180-1184.
PubMed
13) Yoo C, Hwang JY, Kim JE, et al : A randomised phase II study of modified FOLFIRI. 3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009 ; 101 : 1658-1663.
PubMed
14) Pelzer U, Schwaner I, Stieler J, et al : Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer : A phase III-study from the German CONKO-study group. Eur J Cancer 2011 ; 47 : 1676-1681.
 
15) Pelzer U, Kubica K, Stieler J, et al : A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008 ; 26 suppl : 215s (abstr 4508).
 
16) Okusaka T, Ohkawa S, Isayama H, et al : Randomized phase II trial of S-1 versus S-1 plus oxaliplatin (SOX) in patients with gemcitabine refractory pancreatic cancer. European Society for Medical Oncology 2012 Congress. Ann Oncol 2012 ; 23 suppl : 9 (abstr 728).
 
17) Mizuno N, Yamao K Komatsu Y, et al : Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer 2013 Gastrointestinal Cancers Symposium. J Clin Oncol. 2013 ; 31 suppl : (abstr 263).
 
18) Okusaka T, Ueno M, Omuro Y, et al : Randomized phase III study comparing S-1 plus Leucovorin (SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC). European Cancer Congress 2013. Eur J Cancer 2013 ; 49 suppl 2 : S611 (abstr 2578).
 
19) Von Hoff D, Li CP, Wang-Gillarn A, et al : NAPOLI 1 : randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. ESMO World Congress on Gastrointestinal Cancer 2014. (abstr O-0003).
 
20) Ryan DP, Reddy SG, Bahary N, et al : TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC). 2013 Gastrointestinal Cancers Symposium. J Clin Oncol 2012 ; 30 suppl : 34 (abstr 325).
 
21) Kobayashi N, Seto K, Orikawa Y, et al : Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells. Biol Pharm Bull 2010 ; 33 : 216-222.
PubMed
22) Meyer T, Caplin ME, Palmer DH, et al : A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. Eur J Cancer 2010 ; 46 : 526-533.
PubMed
23) Hurwitz H, Uppal N, Wagner SA, et al : Johanna C. A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 2014 ; 32 suppl : (abstr 4000).
 
P.52 掲載の参考文献
1) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-2413.
 
2) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
3) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-1966.
 
4) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
5) 里井壯平, 柳本泰明, 豊川秀吉, ほか : 膵癌に対する腹腔鏡下細胞診と生検の意義. 胆と膵 2010 ; 31 : 869-873.
Medical*Online
6) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Pancreatic Adenocarcinoma. Version 1. 2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site [Accessed 20 January 2014].)
 
7) Therasse P, Arbuck SG, Eisenhauer EA, et al : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 ; 92 : 205-216.
 
8) Thomassen I, Lemmens VE, Nienhuijs SW, et al : Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin : a population-based study. Pancreas 2013 ; 42 : 72-75.
PubMed
9) Markman M, Rowinsky E, Hakes T, et al : Phase I trial of intraperitoneal taxol : a Gynecologic Oncology Group Study. J Clin Oncol 1992 ; 10 : 1485-1491.
 
10) Armstrong DK, Bundy B, Wenzel L, et al : Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Eng J Med 2006 ; 354 : 34-43.
 
11) Ishigami H, Kitayama J, Kaisaki S, et al : Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010 ; 21 : 67-70.
 
12) Ishigami H, Kitayama J, Otani K et al : Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 2009 ; 76 : 311-314.
 
13) Kodera Y, Imano M, Yoshikawa T, et al : A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). Jpn J Clin Oncol 2011 ; 41 : 283-286.
PubMed
14) Shukuya T, Yasui H, Boku N, et al : Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites : a retrospective study. Jpn J Clin Oncol 2010 ; 40 : 1135-1138.
PubMed
15) Takahara N, Isayarna H, Nakai Y, et al : Intravenous and Intraperitoneal Paclitaxel with S-1 for Refractory Pancreatic Cancer with Malignant Ascites : an Interim Analysis. J Gastrointest Cancer 2014 Mar 28. [Epub ahead of print].
 
P.60 掲載の参考文献
1) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-992.
PubMed
2) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-2413.
 
3) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-1966.
 
4) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
5) van der Bruggen P, Traversari C, Chomez P, et al : A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 ; 254 : 1643-1647.
PubMed
6) Galon J, Costes A, Sanchez-Cabo F, et al : Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 ; 313 : 1960-1964.
PubMed
7) Holmes Jp, Gates JD, Benavides LC, et al : Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence : from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008 ; 113 : 1666-1675.
 
8) Von Hoff D, Ervin T, Arena F : Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 2012 ; 30 (suppl 34) : Abstract LBA148.
 
9) Khong HT, Restifo NP : Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002 : 3 : 999-1005.
PubMed
10) Ryschich E, N6tzel T, Hinz U, et al : Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005 ; 11 : 498-504.
 
11) Marincola FM, Jaffee EM, Hicklin DJ, et al : Escape of human solid tumors from T-cell recognition : molecular mechanisms and functional significance. Adv Immunol 2000 ; 74 : 181-273.
 
12) Garrido F, Algarra I, Garcia-Lora AM : The escape of cancer from T lymphocytes : immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Imrnunother 2010 ; 59 : 1601-1606.
 
13) Ishigami S, Natsugoe S, Nakajo A, et al : HLA-class I expression in gastric cancer. J Surg Oncol 2008 ; 97 : 605-608.
 
14) Tsukahara T, Kawaguchi S, Torigoe T, et al : Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006 ; 97 : 1374-1380.
 
15) Kitamura H, Torigoe T, Asanuma H, et al : Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 2007 ; 178 : 692-696.
PubMed
16) Teicher BA : Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007 ; 13 : 6247-6251.
PubMed
17) Ichihara F, Kono K, Takahashi A, et al : Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003 ; 9 : 4404-4408.
PubMed
18) Yu P, Steel JC, Zhang M, et al : Simultaneous biockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010 ; 16 : 6019-6028.
 
19) Itakura J, Ishiwata T, Friess H, et al : Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997 ; 3 : 1309-1316.
PubMed
20) Seo Y, Baba H, Fukuda T, et al : High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000 ; 88 : 2239-2245.
 
21) Folkman J : Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 ; 1 : 27-31.
PubMed
22) Li Y, Wang MN, Li H, et al : Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002 ; 195 : 1575-1584.
 
23) Wada S, Tsunoda T, Baba T, et al : Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005 ; 65 : 4939-4946.
PubMed
24) Ishizaki H, Tsunoda T, Wada S, et al : Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 2006 ; 12 : 5841-5849.
PubMed
25) Suzuki H, Onishi H, Wada J, et al : VEGFR2 is selectively expressed by FOxP3high CD4+ Treg. Eur J Immunol 2010 ; 40 : 197-203.
PubMed
26) Miyazawa M, Ohsawa R, Tsunoda T, et al : Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010 ; 101 : 433-439.
PubMed
27) Okamoto I, Arao T, Miyazaki M, et al : Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci 2012 ; 103 : 2135-2138.
PubMed
28) Zucker DM, Yang S : Inference for a family of survival models encompassing the proportional hazards and proportional odds models. Stat Med 2006 ; 25 : 995-1014.
PubMed
29) O'day SJ, Maio M Chiarion-Sileni V, et al : Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma : a multicenter single-arm phase II study. Ann Oncol 2010 ; 21 : 1712-1717.
PubMed
30) Wolchok JD, Hoos A, O'Day S, et al : Guidelines for the evaluation of immune therapy activity in solid tumors : immune-related response criteria. Clin Cancer Res 2009 ; 15 : 7412-7420,
PubMed
31) Kono K Iinuma H, Akutsu Y, et al : Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012 ; 10 : 141.
PubMed
32) Wolchok JD, Kluger H, Callahan MK et al : Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 ; 369 : 122-133.
PubMed
33) Butterfield LH, Palucka AK, Britten CM, et al : Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011 ; 17 : 3064-3076.
PubMed
34) Disis ML : Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011 ; 60 : 433-442.
PubMed
35) Hirayama M, Nishikawa H, Nagata Y, et al : Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. Eur J Immunol 2013 ; 43 : 989-1000.
PubMed
36) Iwahashi M, Katsuda M, Nakamori M, et al : Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 2010 ; 101 : 2510-2517.
PubMed
37) Topalian SL, Hodi FS, Brahmer JR, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 ; 366 : 2443-2454.
PubMed
P.70 掲載の参考文献
1) 松野正紀 : 日本膵臓学会膵癌登録20年間の総括. 膵臓 2003 ; 18 : 97-169.
 
2) He S-x, xiong L-L, Yao S-S, et al : The preclinical research of high intensity focused ultrasound. J Beijing Med Univ 1999 ; 31 : 573-576.
 
3) Dubinsky TJ, Cuevas C, Dighe MK, et al : High-intensity focused ultrasound : current potential and oncologic applications. AJR Am J Roentgenol 2008 ; 190 : 191-199.
PubMed
4) Sofuni A, Moriyasu F, Sano T, et al : The current potential of high-intensity focused ultrasound for pancreatic carcinoma. J Hepatobiliary Pancreat Sci 2011 ; 18 : 295-303.
PubMed
5) (社) 日本超音波医学会 機器及び安全に関する委員会編, 超音波診断装置の安全性に関する資料. 2011.
 
6) Xiong LL, He CJ, Yao SS, et al : The preliminary clinical results of the treatment for advanced pancreatic carcinoma by high intensity focused ultrasound [in Chinese]. Chin J Gen Surg 2001 ; 16 : 345-347.
 
7) Xie Derong, Chen Daijia, Teng Hong, et al : The preliminary clinical study of high intensity focused ultrasound combination with gemcitabine in treatment for advanced pancreatic carcinoma. Lin Nan Modern Clin Surg J 2001 ; 1 : 226-228.
 
8) Wang X, Sun JZ : Preliminary study of high intensity focused ultrasound in treating patients with advanced pancreatic carcinoma [in Chinese]. Chin J Gen Surg 2002 ; 17 : 654-655.
 
9) He SX, Wang GM : The noninvasive treatment of 251 cases of advanced pancreatic cancer with focused ultrasound surgery. In : Andrew MA, Crum LA, Vaezy S, editors. Proceedings from the 2nd International Symposium on Therapeutic Ultrasound. Seattle : University of Washington ; 2002 : 51-56.
 
10) Xie DR, Chen D, Teng H : A multicenter nonrandomized clinical study of high intensity focused ultrasound in treating patients with local advanced pancreatic carcinoma [in Chinese]. Chin J Clin Oncol 2003 ; 30 : 630-634.
 
11) Xu YQ, Wang GM, Gu YZ, et al : The acesodyne effect of high intensity focused ultrasound on the treatment of advanced pancreatic carcinoma [in Chinese]. Clin Med J China 2003 ; 10 : 322-323.
 
12) Yuan C, Yang L, Yao C : Observation of high intensity focused ultrasound treating 40 cases of pancreatic cancer [in Chinese]. Chin J Clin Hepatol 2003 ; 19 : 145-146.
 
13) Wang RS, Mu QX, Liu LX, et al : A clinical study of thermotherapy of HIFU in combination with chemotherapy on treating advanced pancreatic cancer [in Chinese]. Acta Nanjing Med Univ 2003 ; 23 : 460-463.
 
14) Gu Y, Wang G, Xia H, et al : Application of high intensity focused ultrasound in treating 45 cases of carcinoma of the pancreas [in Chinese]. Fudan Univ J Med Sci 2004 ; 31 : 135-141.
 
15) Wu F, Wang ZB, Zhu H, et al : Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer : initial experience. Radiology 2005 ; 236 : 1034-1040.
PubMed
16) Sofuni A, Moriyasu F, Sano T, et al : Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World J Gastroenterol 2014 ; 20 : 9570-9577.
PubMed
P.76 掲載の参考文献
1) 日本内視鏡外科学会学術委員会 : 内視鏡外科手術に関するアンケート調査-第11回集計結果報告-. 日内視鏡外会誌 2012 ; 17 : 571-694.
 
2) クリニカル・クエスチョン 2 外科的治療法. 日本膵臓学会膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013 ; 73-75.
 
3) Cuschieri A : Laparoscopic surgery of the pancreas. J R Coll Surg Edlnb 1994 ; 39 : 178-184.
 
4) Cuschieri A, Jakimowicz JJ, van Spreeuwel J : Laparoscopic distal 70%pancreatectomy and splenectomy for chronic pancreatitis. Ann Surg 1996 ; 223 : 280-285.
PubMed
5) Ammori BJ, Ayiomamitis GD : Laparoscopic pancreaticoduodenectomy and distal pancreatectomy : a UK experience and a systematic review of the literature. Surg Endosc 2011 ; 25 : 2084-2099.
 
6) Velanovich V : Case-control cornparison of laparoscopic versus open distal pancreatectomy. J Gastrointest Surg 2006 ; 10 : 95-98.
PubMed
7) Baker MS, Bentrem DJ, Ujiki MB, et al : A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery 2009 ; 146 : 635-645.
PubMed
8) Kooby DA, Gillespie T, Bentrem D, et al : Left-sided pancreatectomy : amulticenter comparison of laparoscopic and open approaches. Ann Surg 2008 ; 248 : 438-446.
 
9) Bausch D, Keck T : Laparoscopic pancreatic resection. Langenbecks Arch Surg 2013 ; 398 : 939-945.
PubMed
10) Nakamura M, Nakashima H : Laparoscopic distal pancreatectomy and pancreatoduodenectomy : is it worthwhile? A meta-analysis of laparoscopic pancreatectomy. J Hepatobiliary Pancreat Sci 2013 ; 20 : 421-428.
PubMed
11) Kooby DA, Hawkins WG, Schmidt CM, et al : A multicenter analysis of distal pancreatectomy for adenocarcinoma : is laparoscopic resection appropriate? J Am Coll Surg 2010 ; 210 : 779-785, 786-787.
 
12) Sui CJ, Li B, Yang JM, et al : Laparoscopic versus open distal pancreatectomy : a meta-analysis. Asian J Surg 2012 ; 35 : 1-8.
PubMed
13) Venkat R, Edil BH, Schulick RD, et al : Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique : a systematic review and meta-analysis. Ann Surg 2012 ; 255 : 1048-1059.
 
14) Fisher SB, Kooby DA : Laparoscopic pancreatectomy for malignancy. J Surg Oncol 2013 ; 107 : 39-50.
PubMed
15) Jayaraman S, Gonen M, Brennan MF, et al : Laparoscopic distai pancreatectomy : evolution of a technique at a single institution. J Am Coll Surg 2010 ; 211 : 503-509.
 
16) DiNorcia J, Schrope BA, Lee MK, et al : Laparoscopic distal pancreatectomy offers shorter hospital stays with fewer complications. J Gastrointest Surg 2010 ; 14 : 1804-1812.
PubMed
17) Fernandez-Cruz L, Cosa R, Blanco L, et al : Curative laparoscopic resection for pancreatic neoplasms : a critical analysis from a single institution. J Gastrointest Surg 2007 ; 11 : 1607-1621.
PubMed
18) Marangos IP, Buanes T, Rosok BI, et al : Laparoscopic resection of exocrine carcinoma in central and distal pancreas results in a high rate of radical resections and long Postoperative survival. Surgery 2012 ; 151 : 717-723.
 
19) Gagner M, Pomp A : Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc 1994 ; 8 : 408-410.
PubMed
20) Gagner M, Palermo M : Laparoscopic Whipple procedure : review of the literature. J Hepatobiliary Pancreat Surg 2009 ; 16 : 726-730.
PubMed
21) Kendrick ML, Cusati D : Total laparoscopic pancreaticoduodenectomy : feasibility and outcome in an early experience. Arch Surg 2010 ; 145 : 19-23.
 
22) Dulcq JL, Wintringer P, Mahajna A : Laparoscopic pancreaticoduodenectomy for benign and malignant disease. Surg Endosc 2006 ; 20 : 1045-1050.
 
23) Pugliese R, Scandroglio I, Sansonna F, et al : Laparoscopic pancreaticoduodenectomy : a retrospective review of 19 cases. Surg Laparosc Endosc Percutan Tech 2008 ; 18 : 13-18.
 
24) Cho A, Yamamoto H, Nagata M, et al : Comparison of laparoscopy-assisted and open pylorus-preserving pancreaticoduodenectomy for periampullary disease. Am J Surg 2009 ; 198 : 445-449.
PubMed
25) Asbun HJ, Stauffer JA : Laparoscopic vs open pancreaticoduodenectomy : overall outcomes and severity of complications using the Accordion Severity Grading System. J Am Coll Surg 2012 ; 215 : 810-819.
PubMed
26) Mesleh MG, Stauffer JA, Bowers SP, et al : Cost analysis of open and laparoscopic pancreaticoduodenectomy : a single institution cornparison. Surg Endosc 2013 ; 27 : 4518-4523.
PubMed
27) Palanivelu C, Jani K, Senthilnathan P, et al : Laparoscopic pancreaticoduodenectomy : Technique and outcomes. J Am Coll Surg 2007 ; 205 : 222-230.
PubMed
28) 森隆太郎, 谷口浩一, 松山隆生, ほか : 当科における非悪性膵疾患に対する尾側膵切除術腹腔鏡手術と開腹手術の比較検討. 横浜医学 2012 ; 63 : 75-81.
 
29) 森隆太郎, 上田倫夫, 國崎主税, ほか : 腹腔鏡補助下膵頭十二指腸切除術を施行した十二指腸GISTの1例. 日外科系連会誌 2013 ; 38 : 1207-1213.
 
P.82 掲載の参考文献
1) Boehm DH, Reichenspurner H, Gulbins H, et al : Early experience with robotic technology for coronary artery surgery. Ann Thorac Surg 1999 ; 68 : 1542-1546.
PubMed
2) GiuHanotti PC, Coratti A, Angelini M, et al : Robotics in general surgery : personal experience in a large community hospital. Arch Surg 2003 ; 138 : 777-784.
 
3) Ballantyne GH : Robotic surgery, telerobotic surgery, telepresence, and telemonitoring. Review of early clinical results. Surg Endosc 2002 ; 16 : 1389-1402.
 
4) Uyama I, Sugioka A, Fujita J, et al : Laparoscopic total gastrectomy with distal pancreatosplenectomy and D2 lymphadenectomy for advanced gastric cancer. Gastric Cancer 1999 ; 2 : 230-234.
PubMed
5) Wakabayashi G : Laparoscopic liver resection : how far can we go? J Hepatobiliary Pancreat Surg 2009 ; 16 : 403-404.
 
6) Kaneko H, Tsutiya M, Otsuka Y, et al : Laparoscopic hepatectomy for hepatocellular carcinoma in cirrhotic patients. J Hepatobiliary Pancreat Surg 2009 ; 16 : 433-438.
 
7) Kendrick ML, Cusati D : Total laparoscopic pancreaticoduodenectomy : feasibility and outcome in an early experience. Arch Surg 2010 ; 145 : 19-23.
 
8) Zureikat AH, Moser AJ, Boone BA, et al : 250 robotic pancreatic resections : safety and feasibility. Ann Surg 2013 ; 258 : 554-562.
PubMed
9) Boggi U, Sibnori S, De Llo N, et al. Feaslblllty of robotic pancreaticoduodenectomy. Br J Surg 2013, 100. 917-925.
 
10) Lai EC, Tang CN : Current status of robot-assisted laparoscopic pancreaticoduodenectomy and distal pancreatectomy : a comprehensive review. Asian J Endsc Surg 2013 ; 6 : 158-164.
 
11) Horiguchi A, Uyama I, Miyakawa S : Robot-assisted laparoscopic pancreaticoduodenectorny. J Hepatobiliary Pancreat Sci 2011 ; 18 : 287-291.
PubMed
12) Horiguchi A, Uyama I, Ito M, et al : Robot-assisted laparoscopic pancreatic surgery. J Hepatobiliary Pancreat Sci 2011 ; 18 : 488-492.
PubMed
13) Horiguchi A, Ishihara S, Ito M, et al : Pancreatoduodenectomy in which dissection of the efferent arteries of the head of the pancreas is performed first. J Hepatobiliary Pancreat Surg 2007 ; 14 : 575-578.
 
14) Horiguchi A, Ishihara S, Ito M, et al : Multislice CT study of pancreatic head arterial dominance. J Hepatobiliary Pancreat Surg 2008 ; 15 : 322-326.
PubMed
15) Kanaya S, Gomi T, Momoi H, et al : Delta-shaped anastomosis in totally laparoscopic Billroth I gastrectomy : new technique of intraabdominal gastroduodenostomy. J Am Coll Surg 2002 ; 195 : 284-287.
PubMed
16) Himpens J, Leman G, Cadiere GB : Telesurgical laparoscopic cjolecystectomy. Surg Endosc 1998 ; 12 : 1091.
PubMed
17) Melvin WS, Needleman BJ, Krause KR, et al : Robotic resection of pancreatic neuroendocrine tumor. J Laparoendosc Adv Surg Tech A 2003 ; 13 : 33-36.
PubMed
18) Vasilescu C, Sgarbura O, Tudor S, et al : Robotic spleen-preserving distal pancreatectomy. A case report. Acta Chir Beig 2009 ; 109 : 396-399.
 
19) Narula VK, Mikami DJ, Melvin WS : Robotic and laparoscopic pancreaticoduodenectomy. a hybrid approach. Pancreas 2010 ; 39 : 160-164.
PubMed
20) Giulianotti PC, Sbrana F, Bianco FM, et al : Robot-assisted laparoscopic pancreatic surgery : single-surgeon experience. Surg Endosc 2010 ; 24 : 1646-1657.
PubMed
21) Zhou NX, Chen JZ, Liu Q, et al : Outcomes of pancreatoduodenectomy with robotic surgery versus open surgery. Int J Med Robotics 2011 ; 7 : 131-137.
 
22) Lai ECH, Yang PC, Tang CN : Robot-assisted laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy--a comparative study. Int J Surg 2012 ; 10 : 475-479.
 
23) Zhang J, wu WM, You L, et al : Robotic versus open pancreatectomy : asystematic review and meta-analysis. Ann Surg Oncol 2013 ; 20 : 1774-1780.
 
P.88 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂小委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2006年版. 金原出版, 2006.
 
2) 日本膵臓学会膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2009年版. 金原出版, 2009.
 
3) 日本膵臓学会膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
4) Maeda A, Boku N, Fukutomi A, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer : Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol 2008 ; 38 : 227-229.
 
5) http://www.suizou.org/2014/news-11.html.
 
6) 中山健夫 : EBMを用いた診療ガイドライン作成・活用ガイド. 金原出版, 2004.
 
7) Minds診療ガイドライン選定部会監, Minds診療ガイドライン作成の手引き 2007. 医学書院 2007.
 
8) 福井次矢, 山口直人監, Minds診療ガイドライン作成手引き 2014. 医学書院 2014.
 

II. 膵癌の診断法

P.97 掲載の参考文献
1) Matsuda A, Matsuda T, Shibata A, et al : Cancer incidence and incidence rates in Japan in 2008 : a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2014 ; 44 : 388-396.
PubMed
2) Honda K, Ono M, Shitashige M, et al : Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol 2013 ; 43 : 103-109.
 
3) Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nature reviews Cancer 2003 ; 3 : 267-275.
PubMed
4) Fenyo D, Eriksson J, Beavis R : Mass spectrometric protein identification using the global proteome machine. Methods Mol Biol 2010 ; 673 : 189-202.
PubMed
5) Brennan DJ, O'Connor DP, Rexhepaj E, et al : Antibody-based proteomics : fast-tracking molecular diagnostics in oncology. Nature reviews Cancer 2010 ; 10 : 605-617.
PubMed
6) Uhlen M, Oksvold P, Fagerberg L, et al : Towards a knowledge-based Human Protein Atlas. Nature biotechnology 2010 ; 28 : 1248-1250.
 
7) Legrain P, Aebersold R, Archakov A, et al : The human proteome project : Current state and future direction. Molecular & cellular proteomics : MCP 2011.
 
8) Anderson NL, Anderson NG : The human plasma proteome : history, character, and diagnostic prospects. Molecular & cellular proteomics : MCP 2002 ; 1 : 845-867.
PubMed
9) Petricoin EF, Zoon KC, Kohn EC, et al : Clinical proteorllics : translating benchside promise into bedside reality. Nature reviews Drug discovery 2002 ; 1 : 683-695.
PubMed
10) Kondo T, Hirohashi S : Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2 D-DIGE) for cancer proteomics. Nature protocols 2006 ; 1 : 2940-2956.
 
11) Ono M, Shitashige M, Honda K, et al : Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Molecular & cellular proteomics : MCP 2006 ; 5 : 1338-1347.
PubMed
12) Chen EI, Yates JR, 3rd. Cancer proteomics by quantitative shotgun proteomics. Molecular oncology 2007 ; 1 : 144-159.
PubMed
13) Issaq HJ, Veenstra TD, Conrads TP, et al : The SELDI-TOF MS approach to proteomics : protein profiling and biomarker identification. Biochemical and biophysical research communications 2002 ; 292 : 587-592.
PubMed
14) Espina V, Mehta AI, Winters ME, et al : Protein microarrays : molecular profiling technologies for clinical specimens. Proteomics 2003 ; 3 : 2091-2100.
PubMed
15) Murakoshi Y, Honda K, Sasazuki S, et al : Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer science 2011 ; 102 : 630-638.
PubMed
16) Olsen JV, Vermeulen M, Santamaria A, et al : Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Science signaling 2010 ; 3 (104) : ra3.
PubMed
17) Yoneyama T, Ohtsuki S, Ono M, et al : Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated alpha-fibrinogen in plasma for pancreatic cancer diagnosis. Journal of proteome research 2013 : 12 : 753-762.
PubMed
18) Honda K Hayashida Y, Umaki T, et al : Possible detection of pancreatic cancer by plasma protein profiling. Cancer research 2005 ; 65 : 10613-10622.
PubMed
19) Honda K, Okusaka T, Felix K, et al : Altered plasma apolipoprotein modifications in patients with pancreatic cancer : protein characterization and multi-institutional validation. PloS one 2012 ; 7 (10) : e46908.
PubMed
P.103 掲載の参考文献
1) Lovat F, Valeri N, Croce CM : MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011 ; 38 : 724-733.
PubMed
2) Calin GA, Cimmino A, Fabbri M, et al : MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008 ; 105 : 5166-5171.
PubMed
3) Bonci D, Coppola V, Musumeci M, et al : The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008 ; 14 : 1271-1277.
PubMed
4) Zhang C, Kang C, You Y, et al : Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kipl in vitro and in vivo. Int J Oncol 2009 ; 34 : 1653-1660.
 
5) Sandhu S, Garzon R : Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 2011 ; 38 : 781-787.
PubMed
6) Tanaka M, Oikawa K, Takanashi M, et al : Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009 ; 4 : e5532.
 
7) Ali S, Almhanna K, Chen W, et al : Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010 ; 3 : 28-47.
PubMed
8) Wang J, Chen J, Chang P, et al : MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease, Cancer Prev Res (Phila) 2009 ; 2 : 807-813.
 
9) Giovannetti E, Funel N, Peters GJ, et al : MicroRNA-21 in pancreatic cancer : correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010 ; 70 : 4528-4538.
PubMed
10) Komatsu S, Ichikawa D, Takeshita H, et al ; Circulating miR-18a : A Sensitive Cancer Screening Biomarker in Human Cancer. In Vivo 2014 ; 28 : 293-297.
PubMed
11) Morimura R Komatsu S, Ichikawa D, et al : Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011 ; 105 : 1733-1740.
PubMed
12) Habbe N, Koorstra JB, Mendell JT, et al : MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009 ; 8 : 340-346.
PubMed
13) Paik WH, Kim HR, Park JK, et al : Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabiner-esistant pancreatic cancer cells by indole-3-carbinol. Anticancer Res 2013 ; 33 : 1473-1481.
 
14) Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al : Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010 ; 327 : 198-201.
PubMed
15) Takeshita F, Patrawala L, Osaki M, et al : Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010 ; 18 : 181-187.
PubMed
16) Ohno S, Takanashi M, Sudo K, et al : Systernically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 2013 ; 21 : 185-191.
PubMed
P.112 掲載の参考文献
1) Kamiyama H, Suzuki K, Maeda T, et al : DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 2012 ; 31 : 5029-5037.
PubMed
2) Suzuki K, Ohnami S, Tanabe C, et al : The genornic damage estimated by arbitrarily primed PCR DNA fingerprinting is useful for the prognosis of gastric cancer. Gastroenterology 2003 ; 125 : 1330-1340.
 
3) Suzuki K, Suzuki I, Leodolter A, et al : Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 2006 ; 9 : 199-207.
PubMed
4) Koizumi K, Alonso S, Miyaki Y, et al : Array-based identification of common DNA methylation alterations in ulcerative colitis. Int J Oncol 2012 ; 40 : 983-994.
PubMed
5) Muto Y, Maeda T, Suzuki K, et al : DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability. BMC Cancer 2014 ; 14 : 466.
PubMed
6) Nones K, Waddell N, Song S, et al : Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer 2014 ; 135 : 1110-1118.
PubMed
7) Biankin AV, Waddell N, Kassahn KS, et al : Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012 ; 491 : 399-405.
PubMed
8) Feldmann G, Beaty R, Hruban RH, et al : Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007 ; 14 : 224-232.
PubMed
9) Fukushige S, Furukawa T, Satoh K, et al : Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res 1998 ; 58 : 4222-4226.
PubMed
10) Ha A, Watanabe H, Yamaguchi Y, et al : Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. Pancreas 2001 ; 23 : 356-363.
 
11) Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362. 1605-1617.
PubMed
12) Ting DT, Lipson D, Paul S, et al : Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 2011 ; 331 : 593-596.
PubMed
13) Zhu Q, Pao GM, Huynh AM, et al : BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011 ; 477 : 179-184.
PubMed
14) Maeda T, Suzuki K, Togashi K, et al : Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. Exp Ther Med 2011 ; 2 : 695-700.
 
15) Okada S, Suzuki K, Takaharu K, et al : Aberrant methylation of the Pleckstrin and Sec7 domain-containing gene is implicated in ulcerative colitis-associated carcinogenesis through its inhibitory effect on apoptosis. Int J Oncol 2012 ; 40 : 686-694.
PubMed
16) Saito M, Suzuki K, Maeda T, et al : The accumulation of DNA demethylation in Sat alpha in normal gastric tissues with Helicobacter pylori infection renders susceptibility to gastric cancer in some individuals. Oncol Rep 2012 ; 27 : 1717-1725.
PubMed
17) Misale S, Yaeger R, Hobor S, et al : Emergence of KRAS mutations and acquired resistance to anti-EGFR, therapy in colorectal cancer. Nature 2012 ; 486 : 532-536.
PubMed
18) Bettegowda C, Sausen M, Leary RJ, et al : Detection of circulating tumor DNA in early- and late-stage human malignancies, Sci Transl Med 2014 ; 6 : 224ra224.
PubMed
19) Yu M, Ting DT, Stott SL, et al : RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012 ; 487 : 510-513.
PubMed
20) Dauksa A, Gulbinas A, Barauskas G, et al : Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease : a pilot study. PLoS One 2012 ; 7 : e37509.
PubMed
P.118 掲載の参考文献
1) 日本膵臓学会 膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
2) Takagi K, Ikeda S, Nakagawa Y, et al : Retrograde pancreatography and cholangiography by fiber duodenoscope. Gastroenterol 1970 ; 59 : 445-452.
 
3) 大井至 : Fiberduodenoscopeによる内視鏡的膵管造影. 日消誌 1969 ; 66 : 880-883.
 
4) 中泉昭彦, 竹中明美 : 膵液細胞診・擦過細胞診の判定基準と有用性. 病理と臨 2009 ; 27 : 1157-1165.
 
5) 松本和也, 斧山巧, 武田洋平, ほか : 膵液細胞診. 肝胆膵 2013 ; 66 : 285-291.
Medical*Online
6) 今村網男, 小泉優子, 小山理香子, ほか : 通常型膵管癌に対する膵管洗浄液細胞診の有用性～胆膵領域の新たな検体採取方法. Gastroenterol Endosc 2009 ; 51 : 84-90.
 
7) 多田稔, 有住俊彦, 小暮宏史, ほか : 膵液細胞診の正診率を挙げるために.胆と膵 2008 ; 29 : 749-750.
 
8) 木村公一, 古川善也, 山崎総一郎, ほか : ENPDチューブ留置での連続膵液採取による細胞診の小膵癌への有用性の検討. 日消誌 2011 ; 108 : 928-936.
 
9) Iiboshi T, Hanada K, Fukuda T, et al : Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer : establishing a new method for the early detection of pancreatic carcinoma in situ. Pancreas 2012 ; 41 : 523-529.
PubMed
10) Mitaka R, Ishihara T, Tada M, et al : Clinical usefulness of repeated pancreatic juice cytology via endoscopic nasopancreatic drainagae tube in patients with pancreatic cancer. J Gastroenterol 2013 ; 48 : 866-873.
 
11) 杉山佳代, 齋藤久美子, 相部晴香, ほか : 内視鏡的経鼻膵管ドレナージ留置下で採取された膵液細胞診の有用性. 日臨細胞広島会誌 2012 ; 33 : 57-62.
 
12) Uchida N, Kamada H, Tsutsumi K, et al : Utility of pancreatic duct brushing for diagllosis of pancreatic carcinoma. J Gastroenterol 2007 ; 42 : 657-662.
 
13) Wakatsuki T, Irisawa A, Bhutani M, et al : Comparative study of diagnostic value of cytologic sampling by endoscopic ultrasonography-guided fine-needle aspiration and that by endoscopic retrograde pancreatography for the management of pancreatic mass without biliary stricture. J Gastroenterol Hepatol 2005 ; 20 : 1707-1711.
PubMed
14) Yamaguchi T, Shirai Y, Nakamura N, et al : Usefulness of brush cytology combined with pancreatic juice cytology in the diagnosis of pancreatic cancer : significance of pancreatic juice cytology after brushing. Pancreas 2012 ; 41 : 1225-1229.
PubMed
15) Ohtsuka T, Tamura K, Ideno N, et al : The role of ERCP in the era of EUS-FNA for preoperative cytological confirmation of resectable pancreatic ductal adenocarcinoma. Surg Today 2014 : Feb. 5 : DOI 10.1008/200595-014-0845-0 (Epub ahead of print)
 
16) 安蘓鉄平, 大塚隆生, 木村英世, ほか : 膵液細胞診および膵液遺伝子検査による膵癌診断. 臨外 2014 ; 69 : 12-16.
 
17) 日本膵臓学会編, 膵癌取扱い規約 第6補訂版. 金原出版, 2013.
 
18) 大塚隆生, 井手野昇, 田村公二, ほか : IPMNに併存する通常型膵癌の診断をどうするか? 胆と膵 2012 ; 33 : 1195-1200.
Medical*Online
19)花田敬士, 飯星智博 : 膵癌早期診断の新たな展開. 日消誌 2013 ; 110 : 2051-2059.
 
20) Sobin LH, Gospodarowicz MK, Wittekind C, eds : International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. 7ed, Oxford : Wiley-Blackwell, 2009.
 
21) Shi C, Fukushima N, Abe T, et al : Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2008 ; 7 : 353-360.
PubMed
22) Fukushima N, Walter KM, Ueki T, et al : Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic diseases. Cancer Res 2006 ; 66 : 1208-1217.
 
23) Sadakari Y, Ohtsuka T, Ohuchida K, et al : MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP 2010 ; 11 : 587-592.
PubMed
24) Hara T, Ikebe D, Odaka A, et al : Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain. Ann Surg 2013 ; 257 : 1103-1111.
 
25) Watanabe H, Ha A, Hu YX, et al : K-ras Mutations in Duodenal Aspirate without Secretin Stimulation for Screening of Pancreatic and Biliary Tract Carcinoma. Cancer 1999 ; 86 : 1441-1448.
PubMed
26) Kanda M, Knight S, Topazian M, et al : Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013 ; 2 : 1024-1033.
PubMed
P.127 掲載の参考文献
1) 日本膵臓学会 編 : 膵癌登録報告 2007. 膵臓 2007 ; 22 : el-427,
 
2) Yamada Y, Mori H, Matsumoto S, et al : Pancreatic adenocarcinoma versus chronic pancreatitis : differentiation with triple-phase helical CT. Abdom Imaging 2010 ; 35 : 134-142.
 
3) Prokesch RW, Chow LC, Beaulieu CF, et al : Local staging of pancreatic carcinoma with multi-detector row CT : use of curved planar reformations-initial experience. Radiology 2002 ; 225 : 759-765.
PubMed
4) 松本俊郎, 森宣, 山田康成, ほか : 膵管癌. 画像診断 2013 ; 33 : 869-878.
Medical*Online
5) 本杉宇太郎, 市川智章, 荒木力 : 膵疾患におけるMR拡散強調像 : 有用性, 限界と新たな展開. 膵臓 2011 ; 26 : 72-78.
Medical*Online
6) 曹博信, 市川智章, 荒木力 : 膵癌の進展度診断. 臨放 2004 ; 49 : 1543-1552.
 
7) Matsumoto S, Mori H, Kiyosue H, et al : "Periipancreatic strands appearance" in pancreatic body and tail carcinoma : evaluation by multi-detector CT with pathological correlation. Abdom Imaging 2012 ; 37 : 602-608.
 
8) Lu DS : Local staging of pancreatic cancer : criteria for unresectability of major vesselsas revealed by pancreatic-phase, thin-section helical CT. AJR 1997 ; 168 : 1439-1443.
 
9) Nakayama Y, Yamashita Y, Kadota M, et al : Vascular encasement by pancreatic cancer : correlation of CT findings with surgical and pathologic results. J Comput Assist Tomogr 2001 ; 25 : 337-342.
PubMed
10) 日本膵臓学会編, 膵癌取扱い規約第6版補訂版. 金原出版株式会社, 東京, 2013.
 
11) Mochizuki K, Gabata T, Kozaka K et al : MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma : correlation with en bloc pathological specimens and diagnostic accuracy. Eur Radiol 2010 ; 20 : 1757-1767.
PubMed
12) Zhang XM, Mitchell DG, Witkiewicz A, et al : Extrapancreatic neural plexus invasion by pancreatic carcinoma : characteristics on magnetic resonance imaging. Abdom Imaging. 2009 ; 34 : 634-641
 
13) 高橋護, 竹原康雄 : 膵. 臨放 2013 ; 58 : 1537-1550.
 
14) 北川裕久, 蒲田敏文, 大坪公士郎, ほか : 画像と病理の対比から学ぶ 膵癌診療アトラス. 学研メディカル秀潤社, 2012. 16-30.
 
15) Motosugi U : Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging : comparison with contrast-enhanced multi-detector row CT. Radiol 2011 ; 260 : 446-453.
 
16) Holzapfel K, Reiser-Erkan C, Fingerle AA, et al : Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging 2011 ; 36 : 179-184.
PubMed
P.133 掲載の参考文献
1) Koyama K, Okamura T, Kawabe J, et al : Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001 ; 15 : 217-224.
PubMed
2) Rose DM, Delbeke D, Beauchamp RD, et al : 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999 ; 229 : 729-737 ; discussion 737-738.
 
3) Kauhanen SP, Komar G, Seppanen MP, et al : A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009 ; 250 : 957-963.
PubMed
4) Tang S, Huang G, Liu J, et al : Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma : a meta-analysis. Eur J Radiol 2011 ; 78 : 142-150.
PubMed
5) Strobel K, Heinrich S, Bhure U, et al : Contrast-enhanced 18F-FDG PET/CT : 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008 ; 49 : 1408-1413.
PubMed
6) 山本立真, 杉浦禎一, 岡村行泰, ほか. FDG-PET陰性膵癌の特徴. 胆と膵 2012, 33. 407-412.
Medical*Online
7) Ozaki Y, Oguchi K, Hamano H et al : Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18fluorodeoxyglucose positron emission tomography. J Gastroenterol 2008 ; 43 : 144-151.
 
8) 清水京子 : 膵腫瘍の良悪性鑑別におけるFDG-PETの意義. 胆と膵 2012 ; 33 : 393-396.
Medical*Online
9) 羽鳥隆, 鈴木修司, 大島奈々, ほか : 膵癌鑑別におけるPETの意義と限界. 臨外 2014 ; 69 : 17-21.
 
10) 高橋秀典, 秋田裕史, 後藤邦仁, ほか : 局所進行膵癌に対する術前化学放射線療法における治療効果予測・予後予測の検討. 胆と膵 2014 ; 35 : 73-79.
Medical*Online
11) Kittaka H, Takahashi H, Ohigashi H, et al : Role of (18) F-fluorodeoxyglucose positron ernission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg 2013 ; 37 : 169-178.
PubMed
12) 日本膵臓学会膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
P.137 掲載の参考文献
1) Yasuda K, Tanaka Y, Fujimoto S, et al : Use of endoscopic ultrasonography in small pancreatic cancer. Scand J Gastroenterol Suppl 1984 ; 102 : 9-17.
PubMed
2) Yamada M, Komoto E, Naito Y, et al : Endoscopic ultrasonography in the diagnosis of pancreatic islet cell tumors. J Ultrasound Med 1991 ; 10 : 271-276.
PubMed
3) Kamata K, Kitano M, Kudo M, et al : Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 2014 ; 46 : 22-29.
PubMed
4) Rosch T, Classen M : Endosonography--what are the limits in gastroenterological diagnostics? Endoscopy 1991 : 23 : 144-146.
PubMed
5) Kitano M, Kudo M, Maekawa K, et al : Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 2004 ; 53 : 854-859.
PubMed
6) Sofuni A, Iijima H, Moriyasu F, et al : Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005 ; 40 : 518-525.
PubMed
7) 北野雅之, 工藤正俊 : 造影EUSのコツ. Gastroenterological endoscopy 2011 ; 53 : 76-86.
 
8) Kitano M, Sakamoto H, Kudo M : Contrast-enhanced endoscopic ultrasound. Dig Endosc 2014 ; 26 Suppl 1 : 79-85.
 
9) Napoleon B, Alvarez-Sanchez MV, Gincoul R, et al : Contrast-enhanced harmonic endoscopic ultrasound in solid lesions of the pancreas : results of a pilot study. Endoscopy 2010 ; 42 : 564-570.
PubMed
10) Fusaroli P, Spada A, Mancino MG, et al : Contrast harmonic echo-endoscopic ultrasound improves accuracy in diagnosis of soiid pancreatic masses. Clin Gastroenterol Hepatol 2010 ; 8 : 629-34, e1-2.
 
11) Matsubara H, Itoh A, Kawashima H, et al : Dynamic quantitative evaluation of contrast-enhanced endoscopic ultrasonography in the diagnosis of pancreatic diseases. Pancreas 2011 ; 40 : 1073-1079.
PubMed
12) Imazu H, Kanazawa K, Mori N, et al : Novel quantitative perfusion analysis with contrast-enhanced harmonic EUS for differentiation of autoimmune pancreatitis from pancreatic carcinoma. Scand J Gastroenterol 2012 ; 47 : 853-860.
PubMed
13) Wiersema MJ, Vilmann P, Giovannini M, et al : Endosonography-guided fine-needle aspiration biopsy : diagnostic accuracy and complication assessment. Gastroenterology 1997 ; 112 : 1087-1095.
PubMed
14) Williams DB, Sahai AV, Aabakken L, et al : Endoscopic ultrasound guided fine needle aspiration biopsy : a large single centre experience. Gut 1999 ; 44 : 720-726.
PubMed
15) 神津照雄, 山尾健次, 入澤篤志 : 超音波内視鏡ガイド下穿刺術ガイドライン. 日本消化器内視鏡学会卒後教育委員会編, 集消化器内視鏡ガイドライン 第3版. 医学書院, 2006 ; 180-187.
 
16) Itoi T, Tsuchiya T, Itokawa F, et al : Histological diagnosis by EUS-guided fine-needle aspiration biopsy in pancreatic solid masses without on-site cytopathologist : a single-center experience. Dig Endosc 2011 ; 23 Suppl 1 : 34-38.
 
17) Hirooka Y, Goto H, Itoh A, et al : Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. J Gastroenterol Hepatol 2003 ; 18 : 1323-1324.
PubMed
18) Shah JN, Fraker D, Guerry D, et al : Melanoma seeding of an EUS-guided fine needle track. Gastrointest Endosc 2004 ; 59 : 923-924.
PubMed
19) Chong A, Venugopal K, Segarajasingam D, et al : Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia. Gastrointest Endosc 2011 ; 74 : 933-935.
PubMed
20) Katanuma A, Maguchi H, Hashigo S, et al : Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. Endoscopy 2012 ; 44 Suppl 2.
 
21) Yoon WJ, Daglilar ES, Fernandez-del Castillo C, et al : Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration : the PIPE Study. Endoscopy 2014 ; 46 : 382-387.
PubMed
22) Fritscher-Ravens A, Brand L Knofel WT, et al : Comparison of endoscopic ultrasound-guided fine needle aspiration for focal pancreatic lesions in patients with normal parenchyma and chronic pancreatitis. Am J Gastroenterol 2002 ; 97 : 2768-2775.
PubMed
23) Varadarajulu S, Tamhane A, Eloubeidi MA : Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Gastrointest Endosc 2005 ; 62 : 728-736.
PubMed

III. 膵癌補助療法の効果判定

P.145 掲載の参考文献
1) Ottle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 ; 297 : 267-277.
 
2) Uesaka K, Fukutomi A, Boku N, et al : Randomized Phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J J Clin Oncol 2013 ; 31 (suppl) : abstr 145.
 
3) Palmer DH, Stocken DD, Hewitt H et al : A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer : gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007 ; 14 : 2088-2096.
PubMed
4) Tajima H, Ohta T, Kitagawa H, et al : Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med 2012 ; 3 : 787-792.
 
5) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
6) Tajima H, Ohta T, Shoji Y, et al : Expression of epithelial-mesenchymal transition markers in locally recurrent hepatocellular carcinoma after radiofrequency ablation. Exp Therap Med 2010 ; 1 : 347-350.
 
7) Xu X, Rao GS, Groh V, et al : Major histocompatibility complex class 1-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer : role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 2011 ; 11 : 194.
 
8) 若月修二, 瀬原淳子 : ADAMファミリーとその機能. 実験医学 2004 ; 22 (増刊) : 125-130.
 
9) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
10) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 ; 369 : 1691-1703.
PubMed
11) Cufi S, Vazquez-Martin A Oliveras-Ferraros C, et al : Metrormin against TGFβ-induced epithelial-to-mesenchymal transition (EMT) : from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010 ; 22 : 4461-4468.
 
12) Okamoto K, Tajima H, Nakanuma S, et al : Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int J Oncol 2012 ; 41 : 573-582.
PubMed
13) Patel S, Mason RM, Suzuki J, et al : Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am J Nephrol 2006 ; 26 : 381-387.
PubMed
14) Watanabe T, Tajima H, Hayashi H, et al : Sodium valproate blocks the transforming growth factor (TGF) -β1 autocrine loop and attenuates the TGF-β1-induced collagen synthesis in human stellate cell line. Int J Mol Med 2011 ; 28 : 919-925.
 
15) Choi HS, Savard CE, Choi JW, et al : Paclitaxel interrupts TGF-beta1 signaling between gallbladder epitheliai cells and myofibroblasts. J Surg Res 2007 : 141 : 183-191.
 
P.150 掲載の参考文献
1) Tajima H, Ohta T, Kitagawa H, et al : Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med 2012 ; 3 : 787-792.
 
2) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013 ; 20 : 3794-3801.
PubMed
3) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
4) Murata Y, Mizuno S, Kishiwada M, et al : Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Pancreas 2011 ; 41 : 130-136.
PubMed
5) Zhao Q, Rashid A, Gong Y, et al : Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 2011 ; 16 : 29-37.
PubMed
6) Chun YS, Cooper HS, Cohen SJ, et al : Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 2011 ; 18 : 3601-3607.
PubMed
7) Matsushita A, Nakamura Y, Sumiyoshi H, et al : A Pilot Study-Neoadjuvant Chemotherapy with Gemcitabine and S1 in Patients with Resectable and Borderline Resectable Pancreatic Cancer. J Carcinog Mutagen. in press.
 
8) Matsuda Y, Fujii T, Suzuki T, et al : Comparison of fixation methods for preservation of morphology, RNAs, and proteins from paraffin-ernbedded human cancer cell-implanted mouse models. J Histochem Cytochern 2011 ; 59 : 68-75.
PubMed
9) Akita H, Zheng Z, Takeda Y, et al : Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009 ; 28 : 2903-2909.
PubMed
10) Marechal R, Bachet JB, Mackey JR, et al : Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012 ; 143 : 664-674, e1-6.
 
11) Matsuda Y, Kure S, Ishiwata T : Nestin and other putative cancer stern cell markers in pancreatic cancer. Med Mol Morphol 2012 ; 45 : 59-65.
 
12) Matsuda Y, Yoshimura H, Ueda J, et al : Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ (null) (NOG) mice. Am J Pathol 2014 ; 184 : 674-685.
 
13) Tajima H, Ohta T, Kitagawa H, et al : Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Oncol Lett 2012 ; 3 : 1186-1190.
PubMed
P.159 掲載の参考文献
1) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 2013 ; 310 : 1473-1481.
PubMed
2) Liao WC, Chien KL, Lin YL, et al : Adjuvant treatments for resected pancreatic adenocarcinoma : a systematic review and network meta-analysis. Lancet Oncol 2013 ; 14 : 1095-1103.
PubMed
3) Uesaka K, Fukutomi A, Boku N, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). JClin Oncol 2013 ; 31 (Suppl) : abstr#145
 
4) クリニカル・クエスチョン3補助療法CQ3-4術後補助化学療法を行うことは推奨されるか? 日本膵臓学会 膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013 ; 92-94.
 
5) 青野高志, 鈴木晋, 金子和弘, ほか : 膵頭体部進行浸潤性膵管癌の治療成績と新たな治療戦略. 日消外会誌 2011 ; 44S : 479.
 
6) White RR, Hurwitz HI, Morse MA, et al : Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001 ; 8 : 758-765.
PubMed
7) Evans DB, Varadhachary GR, Crane CH, et al : Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreas head. J Clin Oncol 2008 ; 26 : 3496-3502.
 
8) Festa V, Andriulli A, Rosaria M, et al : Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer : a meta-analytical evaluation of prospective studies. JOP 2013 : 14 : 618-625.
 
9) Chen Y, Sun XJ, Jiang TH, et al : Combined radiochemotherapy in patients with locally advanced pancreatic cancer : a meta-analysis. World J Gastroenterol 2013 ; 19 : 7461-7471.
 
10) Delcore R, Rodriguez FJ, Forster J, et al. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg 1996 ; 172 : 463-468
 
11) Gebhardt C, Meyer W, Reichel M et al : Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000 ; 385 : 14-20.
PubMed
12) Hirai I, Kimura W, Ozawa K, et al. Perineural invasion in pancreatic cancer. Pancreas 2002, 24. 15-25.
PubMed
13) Takai S, Satoi S, Toyokawa H, et al : Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas : a retrospective, single-institution experience. Pancreas 2003 ; 26 : 243-249.
PubMed
14) Kure S, Kaneko T, Takeda S, et al : Analysis of long-term survivors after surgical resection for invasive pancreatic cancer. HPB (Oxford) 2005 ; 7 : 129-134.
PubMed
15) Schnelldorfer T, Ware AL, Sarr MG, et al : Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma : is cure possible? Ann Surg 2008 ; 247 : 456-462.
PubMed
16) Takahashi H, Ohigashi H, Ishikawa O, et al : Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoraditaion therapy for resectable pancreatic cancer. Ann Surg 2012 ; 255 : 95-102
 
17) Nakao A, Kanzaki A, Fujii T, et al : Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg 2012 ; 255 : 103-108.
PubMed
18) Kurihara C, Yoshimi F, Sasaki K, et al : Impact of portal vein invasion and resection length in pancreatoduodenectomy on the survival rate of pancreatic head cancer. Hepatogastroenterology 2013 ; 60 : 1759-1765.
PubMed
19) Kato H, Usui M, Isaji S, et al : Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer : a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 601-610.
 
20) Konstantinidis IT, Warshaw AL, Allen JN, et al : Pancreatic ductal adenocarcinoma : is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg 2013 ; 257 : 731-736.
 
21) Tempero MA, Arnoletti Jp, Behrman S, et al : Pancreatic adenocarcinoma : clinical practice guideline in oncology. J Natl Compr Canc Netw 2010 ; 8 : 972-1017.
 
22) Hirano S, Kondo S, Hara T, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer : long-term results. Ann Surg 2007 ; 246 : 46-51.
PubMed
23) Trotti A, Colevas AD, Setser A, et al : CTCAE v3.0 : development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003 ; 13 : 176-181
 
24) Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 ; 92 : 205-216.
 
25) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
26) Bassi C, Dervenis C, Butturini G, et al : Postoperative pancreatic fistula : an international study group (ISGPF) definition. Surgery 2005 ; 138 : 8-13.
 
27) Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e1000267.
PubMed
28) Goff SL, Chabot JA : A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer. Cancer J 2012 ; 18 : 602-608.
PubMed
29) Ohigashi H, Ishikawa O, Eguchi H, et al : Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009 ; 250 : 88-95.
PubMed
30) Stokes JB, Nolan NJ, Stelow EB, et al : Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011 ; 18 : 619-627.
PubMed
31) Satoi S, Yanagimoto H, Toyokawa H, et al : Long-term results of surgical resection after preoperative chemoradiation in patients with pancreatic cancer. Pancreas 2012 ; 41 : 333-335.
PubMed
32) Satoi S, Toyokawa H, Yanagimoto H, et al : Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg 2012 ; 16 : 784-792.
PubMed
33) Arvold ND, Ryan DP, Niemierko A, et al : Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012 ; 118 : 3026-3035.
PubMed
34) Jiang H, Du C, Cai M, et al : An evaluation of neoadjuvant chemoradiotherapy for patients with resectable pancreatic ductal adenocarcinoma. HPB Surg 2013 ; 2013 : 298726.
PubMed
35) Pendurthi TK, Hoffman Jp, Ross E, et al : Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 1998 ; 64 : 686-692.
PubMed
36) Andriulli A, Festa V, Botteri E, et al : Neoadjuvant/preoperative gemcitabine for patients with localized pancrteatic cancer : a meta-analysis of prospective studies. Ann Surg Oncol 2012 ; 19 : 1644-1662.
 
37) Barugola G, Partelli S, Crippa S, et al : Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg 2012 ; 203 : 132-139.
PubMed
38) Colbert LE, Hall WA, Nickleach D, et al : Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer 2014 ; 120 : 499-506.
PubMed
39) Xu CP, Xue XJ, Liang N, et al : Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer : a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014 ; 140 : 549-559.
PubMed
40) Heinrich S, Schafer M, Weber A, et al : Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity. results of a prospective phase II trial. Ann Surg 2008 ; 248 : 1014-1022.
PubMed
41) Sho M, Akahori T, Tanaka T, et al : Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci 2013 ; 20 : 197-205.
PubMed
42) Tajima H, Ohta T, Kitagawa H, et al : Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med 2012 ; 3 : 787-792.
 
43) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results frorn a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013 ; 20 : 3794-3801.
 
44) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2014 ; 21 : 148-158.
PubMed
45) Kawai M, Tani M, Terasawa H, et al : Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection : prospective study for 104 consecutive patients. Ann Surg 2006 ; 244 : 1-7.
PubMed
46) Motoi F, Egawa S, Rikiyama T, et al : Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after pancreaticojejunostomy. Br J Surg 2012 ; 99 : 524-531.
PubMed
47) Figueras J, Sabater L, Planellas P, et al : Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduodenectomy. Br J Surg 2013 ; 100 : 1597-1605.
PubMed
48) Takahashi H, Ogawa H, Ohigashi H, et al : Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery 2011 ; 150 : 547-556.
PubMed
49) Lin H, Chang CL, Huang EY, et al : Early-onset sigrnoid colon perforation during concurrent chemoradiation in a patient with cervical cancer. Int J Gynecol Cancer 2004 ; 14 : 381-383.
 
50) Crane CH, Ellis LM, Abbruzzese JL, et al : Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006 ; 24 : 1145-1151.
PubMed
51) Fischer R, Breidert M, Keck T, et al : Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. Saudi J Gastroenterol 2012 ; 18 : 118-121.
PubMed
52) Amikura K, Kobari M, Matsuno S : The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol 1995 ; 17 : 139-146.
PubMed
53) Yokoyama N, Otani T, Hashidate H, et al : Real-time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging. preliminary results of a prospective study. Cancer 2012 ; 118 : 2813-2819.
PubMed
54) Murata Y, Mizuno S, Kishiwada M, et al : Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Pancreas 2012 ; 41 : 130-136.
 
55) Takahashi H, Ohigashi H, Gotoh K, et al : Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 2013 ; 258 : 1040-1050.
PubMed
56) Moutardier V, Magnin V, Turrini O, et al : Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004 ; 60 : 437-443.
PubMed
57) Estrella JS, Rashid A, Fleming JB, et al : Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012 ; 118 : 268-277.
PubMed
58) Tachezy M, Gebauer F, Petersen C, et al : Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma : NEOPA-a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer 2014 ; 14 : 411.
PubMed
P.167 掲載の参考文献
1) 元井冬彦, 川口桂, 青木豪, ほか : 切除企図・切除可能膵癌に対する術前化学療法の有効性. 癌と化療 2013 ; 40 : 1632-1636.
Medical*Online
2) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013 ; 20 : 3794-3801.
PubMed
3) Simosato Y, Oboshi S, Baba K : Histological evaluation of effect of radiotherapy and chemotherapy for carcinoma. Jap J Clin Oncol 1971 ; 1 : 19-35.
 
4) 水間正道, 元井冬彦, 青木修一, ほか : 進展度診断と治療アルゴリズム. 肝胆膵 2014 ; 68 : 865-870.
Medical*Online
5) Patel M, Hoffe S, Malafa M, et al : Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011 ; 104 : 155-161.
PubMed
6) Dudeja V, Greeno EW, Walker SP, et al : Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression. HPB (Oxford) 2013 ; 15 : 661-667.
PubMed
P.176 掲載の参考文献
1) Siegel R, Naishadham D, Jernal A : Cancer statistics, 2013. CA Cancer J Clin 2013 ; 63 : 11-30.
PubMed
2) がん研究振興財団. がんの統計 '13. Available at : http://ganjoho.jp/professional/statistics/backnumber/2013_jp.html. Accessed 12/5/2013.
 
3) Sohn TA, Yeo CJ, Cameron JL. et al : Resected adenocarcinoma of the pancreas-616 patients : results, outcomes, and prognostic indicators. J Gastrointest Surg 2000 ; 4 : 567-579.
PubMed
4) Matsuno S, Egawa S, Fukuyama S, et al : Pancreatic Cancer Registry in Japan : 20 years of experience. Pancreas 2004 ; 28 : 219-230.
PubMed
5) Winter JM, Cameron JL, Campbell KA, et al : 1423 pancreaticoduodenectomies for pancreatic cancer : A single-institution experience. J Gastrointest Surg 2006 ; 10 : 1199-1210.
PubMed
6) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 : 297 : 267-277.
PubMed
7) Uesaka K, Fukutomi A, Boku N, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2013 ; 31 : abstr 145.
 
8) Murakami Y, Uemura K, Sudo T, et al : Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma, Am J Surg 2008 ; 195 : 757-762.
 
9) Kondo N, Murakami Y, Uemura K, et al : Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010 ; 17 : 2321-2329.
PubMed
10) Murakami Y, Uemura K Sudo T, et al : Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. J Surg Oncol 2012 ; 106 : 174-180.
 
11) Mackey JR, Mani RS, Selner M, et al : Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998 ; 58 : 4349-4357.
PubMed
12) Shirasaka T, Shimamato Y, Ohshimo H, et al : Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996 : 7 : 548-557.
 
13) Salonga D, Danenberg KD, Johnson M, et al : Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000 ; 6 : 1322-1327.
PubMed
14) Mizutani Y, Wada H, Fukushima M, et al : The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer 2001 ; 37 : 569-575.
PubMed
15) Farrell JJ, Elsaleh H, Garcia M, et al : Human equilibrative nucleoside transporter l levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009 ; 136 : 187-195.
 
16) Nakayama S, Takeda S, Kawase Y, et al : Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg 2004 ; 240 : 840-844.
PubMed
17) 日本膵臓学会 膵癌診療ガイドライン改定委員会編. 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
18) Kosuge T, Kiuchi T, Mukai K, et al : A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006 ; 36 : 159-165.
PubMed
19) Greenhalf W, Ghaneh P, Neoptolemos JP, et al : Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014 ; 106 : djt347.
 
20) Wei CH, Gorgan TR, Elashoff DA, et al : A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas 2013 ; 42 : 1303-1310.
PubMed
21) Nakagawa N, Murakami Y, Uemura K et al : Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013 ; 153 : 565-575.
PubMed
22) Marechal R, Mackey JR, Lai R, et al : Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010 ; 116 : 5200-5206.
PubMed
23) Kuramochi H, Hayashi K, Uchida K, et al : High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chernother Pharmacol 2008 ; 63 : 85-89.
 
24) Hu YC, Komorowski RA, Graewin S, et al : Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003 ; 9 : 4165-4171.
PubMed
P.183 掲載の参考文献
1) Burris HA 3rd, Moore MJ, Anderson J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : arandomized trial. J Clin Oncol 1997 ; 15 : 2403-2413.
 
2) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Endl J Med 2011 ; 364 : 1817-1825.
 
3) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 ; 369 : 1694-1703.
 
4) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial JAMA 2007 ; 297 : 267-277.
PubMed
5) Ueno H, Kosuge T, Matsuyama Y, et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009 ; 101 : 908-915.
 
6) Yoshitomi H, Togawa A, Kimura F, et al : A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008 ; 113 : 2448-2456.
PubMed
7) Evans DB, Varadhachary GR, Crane CH, et al : Preoperative gemcitabine-based chmoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008 ; 26 : 3496-3502.
 
8) Varadhachary GR, Wolff RA, Crane CH, et al : Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008 ; 26 : 3487-3495.
 
9) Palmer DH, Stocken DD, Hewitt H, et al : Arandomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer : gemcitabine alone versusu gemcitabine combined with cisplatin. Ann Surg Oncol 2007 ; 14 : 2088-2096.
 
10) Motoi E Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-insitutional phase 2 tria1. Ann Surg Oncol 2013 ; 20 : 3794-3801.
 
11) Oh-Ishi, M, Satoh M, Maeda T : Preparative two-dimensional gel electrophoresis with agarose gels in the first dimension for high molecular mass proteins. Electrophoresis 2000 ; 21 : 1653-1669.
PubMed
12) Tomonaga T, Matsushita K, Yamaguchi S, et al : Identification of altered perotein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res 2004 ; 10 : 2007-2014.
PubMed
13) Simiya M, Tomonaga T, Matsushita K, et al : Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma ; clathrin heavy chain and formiminotransferase cyclodeaminase. Hapatology 2008 ; 48 : 519-530.
 
14) Takano S, Togawa A, Yoshitomi H, et al : Annexin H overespression predicts rapid recurrence after surgery in pancreatic cancer patietns undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol 2008 ; 15 : 3157-3168.
 
15) Kagawa S, Takano S, Yoshitomi H, et al : Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res 2012 ; 178 : 758-767.
 
16) Togawa A, Ito H, Kimura F, et al : Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line. Pancreas 2003 ; 27 : 220-224.
PubMed
17) 佐藤守, 曽川一幸, 野村文夫 : 定量的質量分析法の最近の進歩. 日臨検自動化会誌 2012 ; 37 : 175-181.
Medical*Online
18) Ong SE, Blagoev B, Kratchmarova I, et al : Stable isotope labeling by amino acids in cell culture, SI-LAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002 ; 1 : 376-386.
 
19) Ong SE, Kratchmarova I, Mann M, et al : Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). J Proteome Res 2003 ; 2 : 173-181.
PubMed
P.190 掲載の参考文献
1) Ueno H, Kosuge T, Matsuyama Y, et al : A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009 ; 101 : 908-915.
 
2) 日本膵臓学会膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2009年版. 金原出版, 2009.
 
3) Arlt A, Gehrz A, Muerkoster S, et al : Role of NF-IB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines againstgemcitabine-induced cell death. Oncogene 2003 ; 22 : 3243-3251.
 
4) Wang CY, Cusack JC Jr, Liu R, et al : Control of inducible chemoresistance : enhanced antitumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med l999 ; 5 : 412-417.
 
5) Li CP, Chao Y, Chi KH, et al : Concurrent chemoradiotherapy treatment of locally Advanced pancreatic cancer : gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Bio Phys 2003 ; 57 : 98-104.
 
6) Gansauge F, Ramadani M, Pressmar J, et al : NSC-631570 (Ukrain) in the palliative Treatment of pancreatic cancer. Results of a phase II trial 2002 : 386 : 570-574.
 
7) Kunnumakkara AB, Guha S, Krishnan S, et al : Curcumin potentiates antitumor activity of gemcitabinein an orthotopic model of pancreatic cancer through suppression of proliferation, Angiongenesis, and inhibition of nuclear factor-κB regulated gene products. Cancer Res 2007 ; 67 : 3853-3861.
 
8) Hertel LW, Boder GB, Kroin JS, et al : Evaluation of the antitumor activity of gemcitabine (2', 2'-difluoro-2'-deoxycytidine). Cancer Res 1990 ; 50 : 4417-4422.
PubMed
9) Heinemann V, Hertel LW, Grindey GB, et al : Comparison of the cellular pharmacokinetics and toxicity of 2', 2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytokine. Cancer Res 1988 ; 48 : 4024-4031.
PubMed
10) 福岡正博, 根来俊一, 工藤新三, ほか : LY188011 (塩酸) Gemcitabineの非小細胞肺癌に対する後期第II相試験. 癌と化療 1996 : 23 ; 1825-1832
 
11) Okusaka T, Ishii H, Funakoshi A, et al : Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006 ; 57 : 647-653.
PubMed
12) Ioka T, Ikeda M, Ohkawa S, et al : Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan : GEST study. J Clin Oncol 2011 ; 29 : suppl ; abstr. 4007.
 
13) Miura K, Shirasaka T, Yamaue H, et al : S1 as a core anticancer fluoropyrimidine Agent. Expert Opnion on Drug Delivery 2012 ; 9 : 273-286.
 
14) 福島正和 : S1の薬効薬理作用. 癌と化療 2006 ; 33 (s-1) : 19-26.
 
15) Uwagawa T, Paul J, Gocho T, et al : Combination Chemotherapy of Nafamostat Mesilate with Gemcitabine for Pancreatic Cancer Targeting NF-kB Activation. Anticancer Res 2009 ; 29 : 3173-3178.
 
16) Rosa F. Hwang, Kenji Yokoi, Corazon D, et al : Inhibition of Platelet-Derived Growth Factor Receptor Phosphorylation by STI571 (Gleevec) Reduces Growth and Metastasis of Human Pancreatic Cainoma in an Orthotopic Nude Muce Model. Clin Cancer Res 2003 ; 9 : 6534-6544.
 
17) Fujiwara Y, Furukawa K, Haruki K, et al : Nafamostat mesilate can Prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer through nuclear factor kappa-B inhibition. J Hepatobiliary pancreat Sci 2011 ; 18 : 731-739.
PubMed
18) Lindahl : Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997 ; 5323 : 242-245.
PubMed
19) Reuterdahl C, Sundberg C, Rubin K, et al : Tissue localization of beta receptors for platelet-derived growth factor and platelet-derived growth factor B chain during wound repair in humans. J Clin Invest 1993 ; 91 : 2065-2075.
PubMed
20) Furukawa K, Uwagawa T, Iwase R, et al : Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Anticancer Res 2012 ; 11 : 5121-5126.
PubMed
21) Chen J, R6cken C, Nitsche B, et al : The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett 2006 ; 223 : 328-337.
 

IV. Borderline resectable膵癌の診断と手術

P.195 掲載の参考文献
1) Matsuno S, Egawa S, Fukuyama S, et al : Pancreatic Cancer Registry in Japan. 20 years of experience. Pancreas 2004 : 28 ; 219-230.
PubMed
2) 日本膵臓学会 膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく 膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
3) http://www.tri-kobe.org/nccn/guideline/pancreas/japanese/pancreatic.pdf
 
4) Satoi S, Yanagimoto H, Toyokawa H, et al : Selective use of staging laparotomy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable cancer. Pancreas 2011 : 40 ; 426-432.
PubMed
5) Callery MP, Chang KJ, Fishman EK, et al : Pretreatment assessment of resectable and borderline resectable pancreatic cancer : expert consecsus statement. Ann Surg Oncol 2009 : 16 ; 1727-1733.
PubMed
6) Chun YS, Milestone BN, Watson JC, et al : Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010 : 17 ; 2832-2838.
PubMed
7) Stokes JB, Nolan NJ, Stelow EB, et al : Preoperative capecitabine and concurrent radiation for borderline resectable cancer. Ann Surg Oncol 2011 : 18 ; 619-627.
PubMed
8) McClaine RJ, Lowy AM, Sussman JJ, et al : Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford) 2010 : 12 : 73-79.
PubMed
9) Brown KM, Siripurapu V, Davidson M, et al : Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 2008 : 195 ; 318-321.
PubMed
10) Sahora K, Kuehrer I, Eisenhut A, et al : NeoGemOx : Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011 : 149 ; 311-320.
PubMed
11) Greer SE, Pipas JM, Sutton JE, et al : Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008 : 206 ; 451-457.
PubMed
12) Hishinuma S, Ogata Y, Tomikawa M, et al : Stomach-preserving distal pancreatectomy with combined resection of the celiac artery : radical procedure for locally advanced cancer of the pancreatic body. J Gastrintest Surg 2007 : 11 ; 743-749.
 
13) Hirano S, Kondo S, Hara T, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic dody cancer : long-term results. Ann Surg 2007 : 246 ; 46-51.
 
14) Okada K, Kawai M, Tani M, et al : Surgical strategy for patients with pancreatic body/tail carcinoma : who should undergo distal pancreatectomy with en-bloc celiac axis resection? Surgery 2013 : 153 ; 365-372.
PubMed
P.203 掲載の参考文献
1) http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
 
2) Nakao A, Kanzaki A, Fujii T, et al : Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg 2012 ; 255 : 103-108.
PubMed
3) Li H, Zeng MS, Zhou KR, et al : Pancreatic adenocarcinoma : the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 2005 : 29 : 170-175.
PubMed
4) Hirano S, Kondo S, Hara T, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer : long-term results. Ann Surg 2007 ; 246 : 46-51.
PubMed
5) Yamada S, Fujii T, Sugimoto H, et al : Aggressive surgery for borderline resectable pancreatic cancer : evaluation of National Comprehensive Cancer Network guidelines. Pancreas 2013 : 42 : 1004-1010.
PubMed
6) Zeng L, Ou G, Itasaka S, et al : TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 2008 ; 99 : 2327-2335.
PubMed
7) Ikeda M Ioka T, Ito Y, et al : A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2013 ; 85 : 163-169.
 
8) Katz MH, Pisters PW, Evans DB, et al : Borderline resectable pancreatic cancer : the importance of this emerging stage of disease. J Am Coll Surg 2008 ; 206 : 833-846.
 
9) 末永雅也, 藤井努, 山田豪, ほか : 術前画像と術後病理組織像に乖離がみられた膵癌術前化学放射線療法の3例. 日消外会誌 2013 : 46 : 106-113.
 
P.212 掲載の参考文献
1) 日本膵臓学会膵癌登録委員会編, 膵癌登録報告 2007. 膵臓 2011 ; 22 : e1-427.
 
2) Sohn TA, Yeo CJ, Cameron JL, et al : Resected adenocarcinoma of the pancreas-616 patients : results, outcomes, and prognostic indicators. J Gastrointest Surg 2000 ; 4 : 567-579.
PubMed
3) Cameron JL, Riall TS, Coleman J, et al : One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006 ; 244 : 10-15.
PubMed
4) National Comprehensive Cancer Network, Inc. : Pancreatic Adenocarcinoma Version 2. 2014. NCCN Guidelines for Treatment of Cancer by Site. Washington, 2014.
 
5) Nakao A, Harada A, Nonami T, et al : Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 1996 ; 12 : 357-361.
PubMed
6) Tian H, Mori H, Matsumoto S, et al : Extrapancreatic neural plexus invasion by carcinomas of the pancreatic head region : evaluation using thin-section helical CT. Radiat Med 2007 ; 25 : 141-147.
PubMed
7) Nagakawa T, Kayahara M, Ueno K, et al : A clinicopathologic study on neural invasion in cancer of the pancreatic head. Cancer 1992 ; 69 : 930-935.
 
8) Makino I, Kitagawa H, Ohta T, et al : Nerve plexus invasion in pancreatic cancer : spread patterns on histopathologic and embryological analyses. Pancreas 2008 ; 37 : 358-365.
PubMed
9) Mitsunaga S, Hasebe T, Kinoshita T, et al : Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol 2007 ; 31 : 1636-1644.
PubMed
10) Zhang XM, Mitchell DG, Witkiewicz A, et al : Extrapancreatic neural plexus invasion by pancreatic carcinoma : characteristics on magnetic resonance imaging. Abdom Imaging 2009 ; 34 : 634-641.
PubMed
11) Tezel E, Kaneko T, Sugimoto H, et al : Clinical significance of intraportal endovascular ultrasonography for the diagnosis of extrapancreatic nerve plexus invasion by pancreatic carcinoma. Pancreatology 2004 ; 4 : 76-81.
PubMed
12) Kaneko T, Nakao A, Inoue S, et al : Extrapancreatic nerve plexus invasion by carcinoma of the head of the pancreas. Diagnosis with intraportal endovascular ultrasonography. Int J pancreatol 1996 ; 19 : 1-7.
 
13) 日本膵臓学会編, 膵癌取扱い規約 第6版. 金原出版, 2009.
 
14) Yoshioka H, Wakabayashi T : Therapeutic neurotomy on head of pancreas for relief of pain due to chronic pancreatitis ; a new technical procedure and its results. AMA Arch Surg 1958 ; 76 : 546-554.
PubMed
15) Yi SQ, Miwa K, Ohta T, et al : Innervation of the pancreas from the perspective of perineural invasion of pancreatic cancer. Pancreas 2003 ; 27 : 225-229.
PubMed
16) Deshmukh SD, Willmann JK, Jeffrey RB : Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma : evaluation with 3D volume-rendered MDCT imaging. AJR Am J Roentgenol 2010 ; 194 : 668-674.
PubMed
17) Kayahara M, Nakagawara H, Kitagawa H, et al : The nature of neural invasion by pancreatic cancer. Pancreas 2007 ; 35 : 218-223.
PubMed
18) Mochizuki K, Gabata T, Kozaka K, et al : MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma : correlation with en bloc pathological specimens and diagnostic accuracy. Eur Radiol 2010 ; 20 : 1757-1767.
PubMed
19)三浦公子 : Thin Slice Table Incremental CE-CTによる膵癌の進展度診断-主に組織所見との対比において-. 日本医放会誌 1991 ; 51 : 245-259.
 
20) Fukuda T, Iwanaga S, Sakamoto I, et al : CT of neural plexus invasion in common bile duct carcinoma. J Comput Assist Tomogr 1998 ; 22 : 351-356.
PubMed
21) Ochotorena IJ, Kiyosue H, Hori Y, et al : The local spread of lower bile duct cancer : evaluation by thin-section helical CT. Eur Radiol 2000 ; 10 : 1106-1113.
PubMed
22) 望月健太郎, 蒲田敏文, 小坂一斗, ほか : 膵管癌の進展度診断-CTと病理組織の対比から-. 画像診断 2010 ; 30 : 1287-1297.
 
23) Esposito I, Kleeff J, Bergmann F, et al : Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008 ; 15 : 1651-1660.
PubMed
24) Gaedcke J, Gunawan B, Grade M, et al : The mesopancreas is the primary site for R1 resection in pancreatic head cancer : relevance for clinical trials. Langenbecks Arch Surg 2010 ; 395 : 451-458.
PubMed
P.218 掲載の参考文献
1) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. Jama 2007 ; 297 : 267-277.
PubMed
2) Ueno H, Kosuge T, Matsuyama Y, et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009 ; 101 : 908-915.
 
3) Chen JW, Bhandari M, Astill DS, et al : Predicting patient survival after pancreaticoduodenectomy for malignancy : histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford) 2010 ; 12 : 101-108.
PubMed
4) Takahashi H, Ohigashi H, Ishikawa O, et al : Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg 2012 ; 255 : 95-102.
PubMed
5) Farnell MB, Pearson RK, Sarr MG, et al : A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005 ; 138 : 618-628.
PubMed
6) Jang JY, Kang MJ, Heo JS, et al : A Prospective Randomized Controlled Study Comparing Outcomes of Standard Resection and Extended Resection, Including Dissection of the Nerve Plexus and Various Lymph Nodes, in Patients With Pancreatic Head Cancer. Ann Surg 2013.
 
7) Yoshioka H, Wakabayashi T : Therapeutic neurotomy on head of pancreas for relief of pain due to chronic pancreatitis ; a new technical procedure and its results. AMA Arch Surg 1958 ; 76 : 546-554.
PubMed
8) Deshmukh SD, Willmann JK, Jeffrey RB : Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma : evaluation with 3D volume-rendered MDCT imaging. AJR Am J Roentgenol 2010 ; 194 : 668-674.
PubMed
9) Patel BN, Giacomini C, Jeffrey RB, et al : Three-dimensional volume-rendered multidetector CT imaging of the posterior inferior pancreaticoduodenal artery : its anatomy and role in diagnosing extrapancreatic perineural invasion. Cancer Imaging 2013 ; 13 : 580-590.
PubMed
10) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized corltroUed trial. J Hepatobiliary Pancreat Sci 2012 ; 19 : 230-241.
 
P.226 掲載の参考文献
1) Wagner M, Redaelli C, Lietz M, et al : Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004 ; 91 : 586-594.
PubMed
2) Sperti C, Pasquali C, Piccoli A, et al : Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997 ; 21 : 195-200.
PubMed
3) Kawabata Y, Tanaka T, Nishi T, et al : Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Euro J Surg Oncol 2012 ; 38 : 574-579.
 
4) Kawabata Y, Nishi T, Tanaka T, et al : Pancreaticoduodenectomy with Total meso-pancreatoduodenum Excision for Periampullary Carcinoma. Shimane J Medical Science 2014 ; 30 : 69-76.
 
5) Kawabata Y, NishiT, Tanaka T, et al : Safety and Feasibility of a pancreaticoduodenectomy with total meso-pancreatoduodenum excision : analysis in various periampullary disorders. Hepatogastroenterology 2014 ; 131 : 821-827.
 
6) 川畑康成, 林彦多, 田島義証 : 血管合併切除膵癌の治療成績. 島根医学 2014 ; 34 (2) : 21-27.
 
7) National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Avaiable at : http://www.nccn.org/professionals/physician_gls/default.asp.
 
8) 柿田章, 吉田宗紀 : 膵腸吻合 : 密着吻合法. 臨外 54 ; 891-896 : 1999.
 
P.233 掲載の参考文献
1) National comprehensive cancer network (NCCN). Clinical Practice Guideline in Oncology (NCCN guide-lines). Pancreatic adenocarcinoma Ver 1.2013. http://www.nccn.org/professionals/physician-gls/pdf/pancreatic.pdf
 
2) Takahashi S, Kinoshita T, Konishi M, et al : Borderline resectable pancreatic cancer : rationale for multidisciplinary treatment. J Hepatobilialy Pancreat Sci 2011 ; 18 : 567-574.
 
3) Pessaux P, Varma D, Arnaud JP : Pancreaticoduodenectomy : superior mesenteric artery first approach. J Gastrointest Surg 2006 ; 10 : 607-611.
PubMed
4) Weitz J, Rahbari N, Koch M, et al : The "artery first" approach for resection of pancreatic head cancer. J Am Coll Surg 2010 ; 210 : e1-4.
PubMed
5) Shrikhande SV, Barreto SG, Bodhankar YD, et al : Superior mesenteric artery first combined with uncinate process approach versus uncinate process first approach in pancreatoduodenectomy : a comparative study evaluating perioperative outcomes. Langenbecks Arch Surg 2011 ; 396 : 1205-1212.
PubMed
6) Sanjay P, Takaori K, Govil S, st al : 'Artery-first' approaches to pancreatoduodenectomy. Br J Surg 2012 ; 99 : 1027-1035.
 
7) Kurosaki I, Minagawa M, Takano K, et al : Left posterior approach to the superior mesenteric vascular pedicle in pancreaticoduodenectomy for cancer of the pancreatic head. JOP 2011 ; 12 : 220-229.
 
8) Cho A, Yamamoto H, Kainuma O : Tips of laparoscopic pancreaticoduodenectomy : superior mesenteric artery first approach (with video). J Hepatobiliary Pancreat Sci 2014 ; 21 : E19-21.
PubMed
9) Nakao A, Takagi H : Isolated pancreatectomy for pancreatic head carcinoma using catheter bypass of the portal vein. Hepatogastroenterology 1993 ; 40 : 426-429.
PubMed
10) 中尾昭公, 大島健司, 越川克己, ほか : 膵頭部癌に対する膵頭十二指腸切除術-Mesenteric approachとIsolated PD-. 外科治療 2011 ; 105 : 217-221.
 
11) Horiguchi A, Ishihara S, Ito M, et al : Multislice CT study of pancreatic head arterial dominance. J Hepatobiliary Pancreat Surg 2008 ; 15 : 322-326.
PubMed
P.240 掲載の参考文献
1) National Comprehensive Cancer Network (NCCN) Clinical Pancreatic Guidelines in Oncology : Pancreatic Adenocarcinoma. [http://www.nccn.org/professionals/physician_gls/pdf//pancreatic.pdf]
 
2) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012 ; 19 : 230-241.
 
3) Xu X, Zhang H, Zhou P, et al : Meta-analysis of the efficacy of pancreatoduodenectomy with extended lymphadenectomy in the treatment of pancreatic cancer. World J Surg Oncol 2013 ; 11 : 311.
 
4) Bockhorn M, Burdelski C, Bogoevski D, et al : Arterial en bloc resection for pancreatic carcinoma. Br J Surg 2011 ; 98 : 86-92.
PubMed
5) Yekebas EF, Bogoevski D, Cataldegirmen G, et al : En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels : perioperative outcome and long-term survival in 136 patients. Ann Surg 2008 ; 247 : 300-309,
PubMed
6) Sa Cunha A, Rault A, Laurent C, et al : Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 2005 ; 201 : 359-365,
PubMed
7) Schnelldorfer T, Ware AL, Sarr MG, et al : Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma : is cure possible? Ann Surg 2008 ; 247 : 456-62.
PubMed
8) 元井冬彦, 力山敏樹, 片寄友, ほか : Stage IV 局所進行膵癌の治療戦略 : 術前治療 (NAC) とR0切除を目的とした後腹膜一括切除 (en-bloc dissection : EBD). 消化器内科 2010 : 50 : 288-296.
 
9) 元井冬彦, 力山敏樹, 片寄友, ほか : 膵癌の治療戦略 術前治療とR0切除をめざした後腹膜一括郭清. 外科 2010 : 72 : 734-742.
 
10) 日本膵癌学会 膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版株式会社, 2013,
 
11) Gaedcke J, Gunawan B, Grade M, et al : The mesopancreas is the primary site for R1 resection in pancreatin head cancer : relevance for clinical trials. Langenbecks Arch Surg 2010 : 395 : 451-458.
 
12) Adham M, Singhirunnusorn J : Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors. Eur J Surg Oncol 2012 ; 38 : 340-345.
PubMed
13) Jang JY, Kang MJ, Heo JS, et al : A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 2014 : 259 : 656-664.
PubMed
P.246 掲載の参考文献
1) Dulucq JL, Wintringer P, Mahajna A : Laparoscopic pancreaticoduodenectomy for benign and malignant diseases. Surg Endosc 2006 ; 20 : 1045-1050.
PubMed
2) Palanivelu C, Jani K, Senthilnathan P, et al : Laparoscopic pancreaticoduodenectomy : technique and outcomes. J Am Coll Surg 2007 ; 205 : 222-230.
PubMed
3) Kendrick ML, Cusati D : Total laparoscopic pancreaticoduodenectomy. Arch Surg 2010 ; 145 : 19-23.
 
4) Mesleh MG, Stauffer JA, Asbun HJ : Minimally invasive surgical techniques for pancreatic cancer : ready for prime time?. J Hepatobiliary Pancreat Sci 2013 ; 20 : 578-582.
PubMed
5) Kim SC, Song KB, Jung YS, et al : Short-term clinical outcomes for 100 consecutive cases of laparoscopic pylorus-preserving pancreatoduodenectomy : improvement with surgical experience. Surg Endosc 2013 ; 27 : 95-103.
PubMed
6) Nakamura Y, Matsumoto S, Matsushita A, et al : Pancreaticojejunostomy with closure of the pancreatic stump by endoscopic linear stapler in laparoscopic pancreaticoduodenectomy : a reliable technique and benefits for pancreatic resection. Asian J Endosc Surg 2012 ; 5 : 191-194.
PubMed
7) Nakamura Y, Uchida E, Nomura T, et al : Laparoscopic pancreatic resection : some benefits of evolving surgical techniques. J Hepatobiliary Pancreat Surg 2009 ; 16 : 741-748.
PubMed
8) Zanelli M, Casadei R, Santini D et al : Pseudomyxoma peritonei associated with intraductal papillary-mucinous neoplasm of the pancreas. Pancreas 1988 ; 17 : 100-102.
 
9) Kato K, Inoue S, Sugimoto H, et al : A case of Pseudomyxoma peritonei associated with intraductal papillary-mucinous neoplasm of the pancreas. Jpn J Gastroenterol Surg 2007 ; 40 : 1822-1827 (Japanese literature with English abstract).
 
10) Shimizu M, Hirokawa M, Manabe T, et al : Cytologic findings in noninvasive intraductal papillary-mucinous carcinoma of the pancreas. Acta Cytol 1999 ; 43 : 243-246.
PubMed
P.250 掲載の参考文献
1) Okada K, Kawai M, Tani M, et al : Surgical strategy for patients with pancreatic body/tail carcinoma : who should undergo distal pancreatectomy with en-bloc celiac axis resection? Surgery 2013 ; 153 : 365-372.
PubMed
2) Okada K, Kawai M, Tani M, et al : Preservation of the Left Gastric Artery on the Basis of Anatomical Features in Patients Undergoing Distal Pancreatectomy with Celiac Axis En-bloc Resection (DP-CAR). World J Surg : In Press.
 
P.255 掲載の参考文献
1) Kondo S, Katoh H, Hirano S, et al : Results of radical distal pancreatectomy with en bloc resection of the celiac artery for locally advanced cancer of the pancreatic body. Langenbecks Arch Surg 2003 ; 388 : 101-106.
PubMed
2) Hirano S, Kondo S, Hara T, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer : long-term results. Ann Surg 2007 ; 246 : 46-51.
PubMed
3) National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2. 2012 ed 2012. Available from : http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
 
4) Hirano S, Kondo S, Tanaka E, et al : Postoperative bowel function and nutritional status following distal pancreatectomy with en-bloc celiac axis resection. Dig Surg 2010 ; 22 : 212-216.
 
5) Kondo S, Katoh H, Omi M, et al : Radical distal pancreatectomy with en bloc resection of the celiac artery, plexus, and ganglions for advanced cancer of the pancreatic body : a preliminary report on perfect pain relief. JOP 2001 ; 2 : 93-97.
 
6) Miura T, Hirano S, Kondo S, et al : A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection : a retrospective cohort study. Surgery 2014 ; 155 : 457-467.
PubMed

V. 術前補助療法の適応と効果

P.265 掲載の参考文献
1) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvernents in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : A randomized trial. J Clin Oncol 1997 ; 15 : 2403-2413.
 
2) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
3) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-1966.
 
4) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
5) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent resection of pancreatic cancer. JAMA 2007 ; 297 : 267-277.
PubMed
6) Fukutomi A, Uesaka K, Boku N et al. JASPAC 01 : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31, 2013 (suppl ; abstr 4008)
 
7) Evans DB, Varadhachary GR Crane CH, et al : Preoperative Gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008 ; 26 : 3496-3502.
 
8) Satoi S, Yanagimoto H, Toyokawa H, et al : Surgical results following pre-operative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009 ; 38 : 282-288.
 
9) Ohigashi H, Ishikawa O, Eguchi H, et al : Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009 ; 250 : 88-95.
PubMed
10) National Comprehensive Cancer Network. NCCN CIinical Practice Guidelines in Oncology (NCCN Guidelines). Pancreatic Adenocarcinoma. Version 1. 2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site [Accessed 20 January 2014].
 
11) Therasse P, Arbuck SG, Eisenhauer EA, et al : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States. National Cancer Institute of Canada. J Natl Cancer Inst 2000 ; 92 : 205-216.
 
12) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
13) Takai S, Satoi S, Toyokawa H, et al. Clinicopathological evaluation after resection for ductal adenocarcinoma of the pancreas : a retrospective, single-institution experience. Pancreas 2003 ; 26 : 243-249.
PubMed
14) 日本膵臓学会 膵癌登録委員会編 : 膵癌登録報告 2007. 膵臓 2011 ; 22 : e39-44.
 
15) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the JapaneseSociety of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2014 ; 21 : 148-158.
PubMed
16) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gelncitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013 ; 20 : 3794-3801.
PubMed
17) 元井冬彦, 川口桂, 青木豪, ほか : 切除企図・切除可能膵癌に対する術前化学療法の有効性. 癌と化療 2013 ; 40 : 1632-1636.
Medical*Online
P.273 掲載の参考文献
1) Vaccaro V, Sperduti l, Milella M : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 365 : 768-769.
 
2) 長田真二, 小森充嗣, 徳山泰治, ほか : 進行膵癌に対する新しい治療戦略の確立. Biotherapy 2010 ; 24 : 144-150.
Medical*Online
3) Osada S, Saksashita F, Hosono Y, et al : Extracellular signal-regulated kinase phosphorylation due to menadione-induced arylation mediates growth inhibition of pancreas cancer. Cancer Chemother Pharmacol 2008 ; 62 : 315-320.
 
4) Hidalgo M : Pancreatic cancer. N Engl J Med 2010 ; 362 : 1605-1617.
PubMed
5) Takahashi S, Kinoshita T, Konishi M, et al : Borderline resectable pancreatic cancer : rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci 2011 ; 18 : 567-574.
PubMed
6) 長田真二, 今井寿, 佐々木義之, ほか : 膵癌への挑戦. -臨床的・基礎的アプローチ-. 岐阜医師会医誌 2010 ; 24 : 111-114.
 
7) National Comprehensive Cancer Network, NCCN clinical practice guideline in oncology. Pancreatic adenocarcinoma. 2014.
 
8) Eisenhauer EA, Therasse P, Bogaerts J, et al : New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 2009 ; 45 : 228-247.
PubMed
9) Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 2009.
 
10) Bassi C, Dervenis C, Butturini G, et al : Postoperative pancreatic fistula : an international study group (ISGPF) definition. Surgery 2005 ; 138 : 8-13.
 
11) Rahbari NN, Garden OJ, Padbury R, et al : Posthepatectomy liver failure : adefinition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011 ; 149 : 713-724.
 
12) Wente MN, Bassi C, Dervenis C, et al : Delayed gastric emptying (DGE) after pancreatic surgery : a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007 ; 142 : 761-768.
 
13) 小野寺時夫, 五関謹秀, 神前五郎 : Stage 4・5 (5は大腸癌) 消化器癌の非治癒切除・姑息手術に対するTPNの適応と限界. 日外会誌 1984 ; 85 : 1001-1005.
 
14) Osada S, Imai H, Okumura N, et al : A modified reconstruction method to prevent critical complications after pancreatoduodenectomy. Hepatogastroenterology 2006 ; 53 : 296-300.
PubMed
15) Osada S, Sanada Y, Tanaka Y, et al : Clinical evaluation of modified reconstruction method after pancreatoduodenectomy. Hepatogastroenterology 2009 ; 56 : 619-623.
PubMed
16) 日本胃癌学会編 : 胃癌取扱い規約 (第14版). 金原出版, 2010 ; 19.
 
17) Takahashi H, Ohigashi H, Gotoh K, et al : Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 2013 ; 258 : 1040-1050.
PubMed
18) Kim EJ, Ben-Josef E, Herman JM, et al : A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013 ; 119 : 2692-2700.
PubMed
19) Satoi S, Toyokawa H, Yanagimoto H, et al : Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg 2012 ; 16 : 784-792.
PubMed
20) Kanda M, Fujii T, Kodera Y, et al : Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 2011 ; 98 : 268-274.
PubMed
21) Naumann P, Habermehl D, Welzel T, et al : Outcorne after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlenther Onkol 2013 ; 189 : 745-752.
PubMed
22) Topkan E, Parlak T, Yapar AF : FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy. Cancer Imaging 2013 ; 13 : 423-428.
 
23) Shultz DB, Chan C, Shaffer JL et al : Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma. Pancreas 2014 ; 43 : 777-783.
PubMed
24) Osada S, Imai H, Sasaki Y, et al : The best choice to achieve zero complications after pancreatoduodenectomy. Surgical Science 2011 ; 2 : 45-51.
 
25) Osada S, Imai H, Sasaki Y, et al : Reconstruction method after pancreaticoduodenectomy. Idea to prevent serious complications. JOP 2012 ; 13 : 1-6.
PubMed
26) Chen Y, Sun XJ, Jiang TH, et al : Combined radiochemotherapy in patients with locally advanced pancreatic cancer : a meta-analysis. World J Gastroenterol 2013 ; 19 : 7461-7471.
 
P.278 掲載の参考文献
1) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-992.
PubMed
2) Varadhachary GR, Tamm EP, Abbruzzese JL, et al : Borderline resectable pancreatic cancer : definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006 ; 13 : 1035-1046.
PubMed
3) NCCN guidelines. (http://www.nccn.org/professionals/physician_gls/tguidelines.asp#site)
 
4) Kato H, Usui M, Isaji S, et al : Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer : a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 [Epub ahead of print].
 
5) Festa V, Andriulli A, Valvano MR, et al : Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer : a meta-analytical evaluation of prospective studies. JOP 2013 ; 14 : 618-625.
PubMed
6) Laurence JM, Tran PD, Morarji K, et al : A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011 ; 15 : 2059-2069,
PubMed
7) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2014 ; 21 : 148-158.
PubMed
8) Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e1000267.
PubMed
9) Satoi S, Yamaue H, Kato K, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 590-600.
PubMed
10) Kadera BE, Sunjaya DB, Isacoff WH, et al : Locally advanced pancreatic cancer : association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA Surg 2014 ; 149 : 145-153.
PubMed
11) Eguchi H, Nagano H, Kobayashi S, et al : A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer. Cancer Chemother Pharmacol 2014 ; 73 : 309-315.
 
P.284 掲載の参考文献
1) Abrams RA, Lowy AM, O'Reilly EM, et al : Combined modality treatment of resectable and borderline resectable pancreas cancer : expert consensus statement. Ann Surg Oncol 2009 ; 16 : 1751-1756.
PubMed
2) Takahashi S, Kinoshita T, Konishi M, et al : Borderline resectable pancreatic cancer : rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci 2011 ; 18 : 567-574.
PubMed
3) Kim HM, Bang S, Park JY, et al : Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 2009 ; 63 : 535-541.
PubMed
4) Shinchi H, Maemura K, Mataki Y, et al : A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 2012 ; 19 : 152-158.
 
5) Sudo K, Yamaguchi T, Ishihara T, et al : Phase II Study of oral s-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 2011 ; 80 : 119-125.
 
6) Ikeda M, Ioka T, lto Y, et al : A Multicenter Phase II Trial of S-1 With Concurrent Radiation Therapy for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics 2013 ; 85 : 163-169.
 
7) Satoi S, Toyokawa H, Yanagimoto H, et al : Neo-adjuvant Chemoradiation Therapy Using S-1 Followed by Surgical Resection in Patients with Pancreatic Cancer. Journal of Gastrointestinal Surgery 2012 ; 16 : 784-792.
PubMed
8) Mukherjee S, Hurt CN, Bridgewater J, et al : Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP) : a multicentre, randomised, phase 2 trial. Lancet Oncology 2013 ; 14 : 317-326.
 
P.290 掲載の参考文献
1) Callery MP, Chang KJ, Fishman EK, et al : Pretreatment assessment of resectable and borderline resectable pancreatic cancer : expert consensus statement. Ann Surg Oncol 2009 ; 16 : 1727-1733.
PubMed
2) Ohigashi H, Ishikawa O, Eguchi H, et al : Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009 ; 250 : 88-95.
PubMed
3) Greer SE, Pipas JM, Sutton JE, et al : Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008 ; 206 : 451-457.
PubMed
4) Gillen S, Schuster T, Buschenfelde CM, et al : Preoperative/Neoadjuvant therapy in pancreatic cancer : A systematic review and meta-analysis of response and resection percentages. PLoS Medicine 2010 ; 7 : 1-15.
 
5) Festa V, Andriulli A, Valvano MR, et al : Neoadjuvant cherno-radiotherapy for patients with borderline resectable pancreatic cancer : A meta-analytical evaluation of prospective studies. JOP 2013 ; 14 : 618-625.
 
6) Andriulli A, Festa V, Botteri E, et al : Neoadjuvant/Preoperative gemcitabine for patients with localized pancreatic cancer : A meta-analysis of prospective studies. Ann Surg Oncol 2012 ; 19 : 1644-1662.
 
7) Stokes JB, Nolan NJ, Stelow EB, et al : Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011 ; 18 : 619-627.
PubMed
8) Eguchi H, Nagano H, Kobayashi S, et al : A phase I trial of combination therapy using gemcitabine and S-1 concorrent with full-dose radiation for resectable pancreatic cancer. Cancer Chemother Pharmacol 2014 ; 73 : 309-315.
 
9) Aiura K, Takahashi S, Matsui J, et al : Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. Pancreatology 2010 ; 10 : 250-258.
 
P.299 掲載の参考文献
1) 日本膵臓学会診療ガイドライン改定委員会編集 : 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013 : 92-94.
 
2) Eisenhauer EA, Therasse P, Bogaerts J, et al : New response evaluation criteria in solid tumours : revised RECIST guidline (version 1.1) Eur J Cancer 2009 ; 45 : 228-247.
 
3) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
4) Kim HM, Bang S, Park JY, et al : Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2009 ; 63 : 535-541.
PubMed
5) Sudo K, Yamaguchi T, Ishihara T, et al : Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011 ; 80 : 119-125.
 
6) Ikeda M, Ioka T, Ito Y, et al : A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiation Oncol Biol Phys 2013 ; 85 : 163-169.
 
7) Hoffman JP, Weese JL, Solin LJ, et al : A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995 ; 169 : 71-77.
PubMed
8) Breslin TM, Hess KR, Harbison DB, et al : Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas : treatment variables and survival duration. Ann Surg Oncol 2001 ; 8 : 123-132.
PubMed
9) Sasson AR, Wetherington RW, Hoffman JP, et al : Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas : analysis of histopathology and outcome. Int J Gastrointest Cancer 2003 : 34 ; 121-128.
PubMed
10) Mehta VK Fisher G, Ford JA, et al : Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001 ; 5 : 27-35.
PubMed
11) Greer SE, Pipas JM, Sutton JE, et al : Effect of neoajuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008 ; 206 : 451-457.
 
12) Yeo CJ, Cameron JL, Lillemoe KD, et al : Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995 ; 221 : 721-731.
PubMed
13) Neuhaus P, Riess H, Post S, et al : Deutsche Krebsgesellschft (CAO/AIO). CONKO-001 : Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 2008 : 26 : abstr LBA4504.
 
14) Ueno H, Kosuge T, Matsuyama Y, et al : A randornized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009 ; 101 : 908-915.
 
15) Uesaka K, Fukutomi A, Boku N, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2013 ; 31 (suppl) : abstr 145.
 
16) Gillen S, Schuster T. Meyer ZBC, et al : Preoperative/neoajuvant therapy in pancreatic cancer : a systemic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e1000267.
 
P.306 掲載の参考文献
1) Paulson AS, Tran Cao HS, Tempero MA, et al : Therapeutic advances in pancreatic cancer. Gastroenterology 2013 ; 144 : 1316-1326.
PubMed
2) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-992.
PubMed
3) Sho M, Akahori T, Tanaka T, et al : Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Sci 2013 ; 20 : 197-205.
PubMed
4) Sho M, Tanaka T, Yamada T, et al : Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Sci 2011 ; 18 : 235-239.
PubMed
5) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 ; 297 : 267-277.
PubMed
6) Ueno H, Kosuge T, Matsuyama Y, et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009 ; 101 : 908-915.
 
7) Evans DB, Varadhachary GR, Crane CH, et al : Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008 ; 26 : 3496-3502.
 
8) Ohigashi H, Ishikawa O, Eguchi H, et al : Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009 ; 250 : 88-95.
PubMed
9) Satoi S, Toyokawa H, Yanagimoto H, et al : Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg. 2012 ; 16 : 784-792.
PubMed
10) Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e1000267.
PubMed
11) 日本膵臓学会膵癌治療診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
12) Takahashi H, Ogawa H, Ohigashi H, et al : Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery 2011 ; 150 : 547-556.
PubMed
13) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
14) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013 ; 20 : 3794-3801.
PubMed
15) Varadhachary GR. Preoperative therapies for resectable and borderiine resectable pancreatic cancer. J Gastrointest Oncoi. 2011 ; 2 : 136-142.
 
16) Festa V, Andriulli A, Valvano MR, et al : Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer : a meta-analytical evaluation of prospective studies. JOP 2013 ; 14 : 618-625.
PubMed
17) Laurence JM, Tran PD, Morarji K, et al : A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011 ; 15 : 2059-2069.
PubMed
18) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2014 ; 21 : 148-158.
PubMed
19) Kang CM, Hwang HK, Choi SH, et al : Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Surg Oncol 2013 ; 22 : 123-131.
PubMed
20) Katz MH, Fleming JB, Bhosale P, et al : Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012 ; 118 : 5749-5756.
 
21) Takahashi H, Ohigashi H, Gotoh K, et al : Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 2013 ; 258 : 1040-1050.
PubMed
22) Valle JW, Palmer D, Jackson R, et al : Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas : ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014 ; 32 : 504-512.
PubMed
P.312 掲載の参考文献
1) World Health Organization : Regional Office for Europe. The European health report 2012 : charting the way to well-being. 2012.
 
2) Howlader N NA, Krapcho M, Neyman N, et al : SEER Cancer Statistics Review, 1975-2009 posted to the SEER web site, April 2012, ed : National Cancer Institute. Bethesda, MD ; 2011.
 
3) National Comprehensive Cancer Network : NCCN practice guidelines for pancreatic cancer, version 2. Available at http://www.nccn.org/professionals/physician_gls/recently_updated.asp.
 
4) Wong JC, Lu DS : Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepato 2008 : 6 : 1301-1308.
 
5) Varadhachary GR, Tamm EP, Abbruzzese JL, et al : Borderline resectable pancreatic cancer : definitions, management and role of preoperative therapy. Ann Surg Oncol 2006 ; 13 : 1035-1046.
PubMed
6) Evans DB, Farnell MB, Lillemore KD, et al : Surgical treatment of resectable and borderline resectable opancreas cancer : expert consensus statement. Ann Surg Oncol 2009 ; 16 : 1736-1744.
 
7) Li H, Zeng MS, Zhou KR, et al : Pancreatic adenocarcinoma : the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 2005 ; 29 : 170-175.
PubMed
8) Hirano S, Kondo S, Hara T, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer. Ann Surg 2007 ; 246 : 46-51.
PubMed
9) Okada K, Kawai M, Tani M, et al : Surgical strategy for patients with pancreatic body/tail carcinoma : Who should undergo distal pancreatectomy with en-bloc celiac axis resection? Surgery 2013 ; 153 : 365-372.
PubMed
10) Okada K, Kawai M, Tani M, et al : Preservation of the left gastric artery on the basis of anatomical features in patients undergoing distal pancreatectomy with celiac axis en-bloc resection (DP-CAR). World J Surg 2014 : in press.
 
11) Hirono S, Kawai M, Tani M, et al : Indication for the use of an interposed graft during portal vein and/or superior mesenteric vein reconstruction in pancreatic resection based on perioperative outcomes. Langenbecks Arch Surg 2014 ; 399 : 461-471.
PubMed
12) Sobin LH, Gospodarowicz MK, Wittekind C, TNM classification of malignant tumors, 7th edition. Wiley-Blackwel, New York, 2009.
 
13) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
14) Fortner JG : Regional resection of cancer of the pancreas : a new surgical approach. Surgery 1973 ; 73 : 307-320.
PubMed
15) Pedrazzoli S, DiCarlo V, Dionigii R, et al : Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas : a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998 ; 228 : 508-517.
 
16) Yeo CJ, Cameron JL, Sohn TA, et al : Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma : comparison of morbidity and mortality and short-term outcome. Ann Surg 1999 ; 229 : 613-622.
 
17) Farnell MB, Pearson RK, Sarr MG, et al : A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005 ; 138 : 618-628.
PubMed
18) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012 ; 19 : 230-241.
 
19) Jang JY, Kang MJ, Heo JS, et al : A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 2014 ; 259 : 656-664.
PubMed
20) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 ; 297 : 267-277.
PubMed
21) Yamaue H, Satoi S, Kanbe T, et al : Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally-advanced and metastatic pancreatic cancer. Cancer Chemother Pharmacol 2014 ; 73 : 97-102.
 
22) Christians KK, Tasi S, Mahmoud A, et al : Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer : a new treatment paradigm? Oncologist 2014 ; 19 : 266-274.
 
P.319 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン作成委員会編 : 科学的根拠考に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
2) Uesaka K, Fukutomi A, Boku N et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer : Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). ASCO-GI Meeting Abstracts 2013 ; 31 : 145.
 
3) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2014 ; 21 : 148-158.
PubMed
4) Mataki Y, Shinchi H, Maemura K, et al : Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy. Gan To Kagaku Ryoho 2013 ; 40 : 1637-1640.
PubMed
5) Tempero MA, Arnoletti JP, Behrman SW, et al : Pancreatic Adenocarcinoma, version 2. 2012 : featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012 ; 10 : 703-713.
 
6) 日本膵臓学会, 膵癌取扱い規約 第6版. 金原出版, 2009.
 
7) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 : 31 : 1640-1648.
PubMed
8) Shinchi H, Maemura K, Mataki Y, et al : A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 2012 ; 19 : 152-158.
 
9) Maemura K Shinchi H, Noma H, et al : Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. Anticancer Res 2008 ; 28 : 2369-2372.
PubMed
10) Watanabe H, Okada M, Kaji Y, et al : New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan To Kagaku Ryoho 2009 ; 36 : 2495-2501.
PubMed
11) Evans DB, Rich TA, Byrd DR, et al : Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992 ; 127 : 1335-1339.
PubMed
12) Leone F, Gatti M, Colombi F, et al : Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer : a single institutional experience. Cancer 2013 ; 119 : 277-284.
PubMed
13) Strobel O, Berens V, Hinz U, et al : Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012 ; 152 : 33-42.
 
14) Sahora K, Kuehrer I, Eisenhut A, et al : NeoGemOx : Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011 ; 149 : 311-320.
PubMed

VI. Initially unresectable膵癌の治療

P.328 掲載の参考文献
1) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 : 15 : 2403-2413.
 
2) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-1966.
 
3) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
4) Ueno H, Ioka T, lkeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
5) Ozaka M, Matsumura Y, Ishii H, et al : Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 2012 ; 69 : 1197-1204.
PubMed
6) Nakai Y, Isayama H, Sasaki T, et al : A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer : GEMSAP study. Br J Cancer 2012 ; 106 : 1934-1939.
 
7) Tajima H, Kitagawa H, Tsukada T, et al : A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Mol Clin Oncol 2013 : 1 : 768-772.
 
8) 日本膵臓学会 膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 2007 ; 22 : e1 -e427.
 
9) Kato K, Kondo S, Hirano S, et al : Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. J Hepatobiliary Pancreat Sci 2011 : 18 : 712-716.
PubMed
10) Massucco P, Capussotti L, Magnino A et al : Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma : analysis of perioperative outcome and survival. Ann Surg Oncol 2006 ; 13 : 1201-1208.
PubMed
11) Katz MH, Fleming JB, Bhosale P, et al : Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012 : 118 : 5749-5756.
 
12) National Comprehensive Cancer Network (NCCN) guidelines. Available from : www.nccn.org.
 
13) 日本膵臓学会膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
14) Cooper AB, Tzeng CW, Katz MH : Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol 2013 ; 14 : 293-310.
PubMed
15) Christians KK, Tsai S, Mahmoud A, et al : Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer : A New Treatment Paradigm? Oncologist 2014 ; 19 : 266-274.
 
16) Tinchon C, Hubmann E, Pichler A, et al : Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 2013 ; 52 : 1231-1233.
 
17) Motoi F, Ishida K, Fujishima F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013 ; 20 : 3794-3801.
PubMed
18) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-992.
PubMed
19) Arvold ND, Ryan DP, Niemierko A, et al : Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012 ; 118 : 3026-3035.
PubMed
20) Colucci G, Giuliani F, Gebbia V, et al : Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma : a prospective, randomized phase III study of the Gruppo Oncologia delrltalia Meridionale. Cancer 2002 ; 94 : 902-910.
 
21) Berlin JD, Catalano P, Thomas JP, et al : Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma : Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002 ; 20 : 3270-3275.
PubMed
22) Nakamura K, Yamaguchi T, Ishihara T, et al : Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006 ; 94 : 1575-1579,
 
23) Ueno H, Okusaka T, Furuse J, et al : Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol 2011 ; 41 : 953-958.
PubMed
24) 道端浩三郎, 石井博, 長山裕之, ほか : Borderline resectable膵癌に対してゲムシタビン+S-1 (GS) 療法が奏効しR0手術を施行し得た膵頭部癌の1例. 膵・胆道癌FRONTIER 2013 ; 3 : 114-115.
Medical*Online
25) 岡田恭穂, 櫻井直樹, 山本久仁治, ほか : 術前化学療法施行後, 腹腔動脈合併尾側膵切除にてR0手術を施行し得た局所進行膵体部癌の1例. 癌と化療 2012 ; 39 : 135-137.
Medical*Online
P.334 掲載の参考文献
1) がんの統計 '13. 国立がん研究センター癌対策室情報センターホームページ : http://ganjohojp/professional/statistics/
 
2) 膵癌登録報告 2007. 日本膵臓学会ホームページ : http://www.suizo.org/
 
3) 日本膵臓学会 膵癌診療ガイドライン改訂委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年度版. 金原出版, 2013.
 
4) Allendorf JD, Lauerman M, Bill A, et al : Meoaduvant chemotherapy and radiation for patients with loccaly inresectable pancreatic adenocarcinoma : fesibility, efficacy, and survival. J Gastrointest Surg 2008 ; 12 : 91-100.
 
5) Turrini O, Viret F, Moureau-Zabotto L, et al : Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancteatic adenocarcinoma. Eur J Surg Oncol 2009 ; 35 : 1306-1311.
 
6) Morganti AG, Massaccesi M, La Torre G, et al : A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010 ; 17 : 194-205.
PubMed
7) Strobel O, Berens V, Hinz U, et al : Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012 ; 152 (3 Suppl 1) : S33-42.
 
8) Kato K, Kondo S, Hirano S, et al : Adjuvant surgical therapy for patients with initially-inresectable pancreatic cancer with long-term favorable responses to chemotherapy. J Hepatobiliary Pancres Sci 2011 ; 18 : 712-716.
 
9) Sasaki T, Isayama H, Aoki T, et al : A R0 Resection Case of Initially Unresectable Metastatic Pancreatic Cancer Downstaged by FOLFIRINOX Therapy. Pancreas 2014 ; 43 : 972-974.
PubMed
10) Adam M, Jaeck D, Lee Borgne J, et al : Lonh-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma : a series of 30 patients collected from 3 institutions. Pancreas 2008 ; 37 : 349-351.
 
11) Satoi S, Yamaue H, Kato K, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 590-600.
PubMed
12) 大腸癌研究会編, 大腸癌治療ガイドライン医師用 2014年度版. 金原出版, 2014.
 
P.341 掲載の参考文献
1) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 2013 ; 310 : 1473-1481.
PubMed
2) Valle JW, Palmer D, Jackson R, et al : Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas : ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014 ; 32 : 504-512.
PubMed
3) Gillen S, Schuster T, Meyer Zum Buschenfelde, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e1000267.
PubMed
4) Cameron JL, Riall TS, Coleman J, et al : One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006 ; 244 : 10-15.
PubMed
5) Buchler MW, Wagner M, Schmied BM, et al : Changes in morbidity after pancreatic resection : toward the end of completion pancreatectomy. Arch Surg 2003 ; 138 : 1310-1314.
PubMed
6) Hartwig W, Hackert T, Hinz U, et al : Multivisceral resection for pancreatic malignancies : risk-analysis and long-term outcome. Ann Surg 2009 ; 250 : 81-87.
PubMed
7) Muller SA, Hartel M, Mehrabi A, et al : Vascular resection in pancreatic cancer surgery : survival determinants. J Gastrointest Surg 2009 ; 13 : 784-792.
PubMed
8) Tseng JF, Tamm EP, Lee JE, et al : Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol 2006 ; 20 : 349-364.
PubMed
9) Strobel O, Berens V, Hinz U, et al : Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012 ; 152 : S33-42.
PubMed
10) Cardenes HR, Moore AM, Johnson CS, et al : A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer : a Hoosier Oncology Group study. Am J Clin Oncol 2011 ; 34 : 460-465.
 
11) Chauffert B, Mornex F, Bonnetain F, et al : Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008 ; 19 : 1592-1599.
 
12) Wanebo HJ, Glicksman AS, Vezeridis MP, et al : Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000 ; 135 : 81-87.
PubMed
13) Snady H, Bruckner H, Cooperman A, et al : Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000 ; 89 : 314-327.
PubMed
14) Aristu J, Canon R, Pardo F, et al : Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003 ; 26 : 30-36.
PubMed
15) Wilkowski R, Thoma M, Schauer R, et al : Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004 ; 28 : 1011-1018.
PubMed
16) Sa Cunha A, Rault A, Laurent C, et al : Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 2005 ; 201 : 359-365.
PubMed
17) Wilkowski R, Thoma M, Bruns C, et al : Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP 2006 ; 7 : 349-360.
PubMed
18) Massucco P, Capussotti L, Magnino A, et al : Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma : analysis of perioperative outcome and survival. Ann Surg Oncol 2006 ; 13 : 1201-1208.
PubMed
19) Lind PA, Isaksson B, Almstrom M, et al : Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol 2008 ; 47 : 413-420.
PubMed
20) Turrini O, Viret F, Moureau-Zabotto L, et al : Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol 2009 ; 35 : 1306-1311.
PubMed
21) Polistina F, Costantin G, Casamassima F, et al : Unresectable locally advanced pancreatic cancer : a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010 ; 17 : 2092-2101.
PubMed
22) Arvold ND, Ryan DP, Niemierko A, et al : Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012 ; 118 : 3026-3035.
PubMed
23) Andriulli A, Festa V, Botteri E, et al : Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer : a meta-analysis of prospective studies. Ann Surg Oncol 2012 ; 19 : 1644-1662.
 
24) Kubota K Hida T, Ishikura S, et al : Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202) : a randomised phase 3 study. Lancet Oncol 2014 ; 15 : 106-113.
PubMed
25) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-2413.
 
26) Conroy T, Desseigne E Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
 
27) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
P.352 掲載の参考文献
1) 厚生労働省平成25年人口動態統計月報年計 (概数) の概況. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai13/index.html
 
2) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-992.
PubMed
3) Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS medicine 2010 ; 7 : e1000267.
PubMed
4) National Comprehensive Cancer Network (NCCN) Practice Guidelines for pancreatic cancer. Secondary National Comprehensive Cancer Network (NCCN) Practice Guidelines for pancreatic cancer. Available at : http://www.nccn.org/clinical.asp (free registration is required for login)
 
5) 日本膵臓学会 膵癌診療ガイドライン改定委員会 (編). 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
6) 伊佐地秀司, 岸和田昌之, 村田泰洋, ほか : 【「切除困難例」への化学療法後の手術-根治切除はどこまで可能か】局所進行/切除不能膵癌に対する化学放射線療法後の根治切除の意義. 臨床外科 2012 ; 67 (1) : 66-72.
 
7) 信岡祐, 岸和田昌之, 伊佐地秀司 : 【見直される膵癌診療の新展開】治療における新展開 膵癌手術の最前線 切除不能膵癌に対するdown-sizing chemo (radio) therapyの意義. 臨外 2014 ; 69 : 49-57.
 
8) Satoi S, Yamaue H, Kato K, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepotobiliary Pancreat Sci 2013.
 
9) Kato K, Kondo S, Hirano S, et al : Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. J Hepotobiliary Pancreat Sci 2011 ; 18 : 712-716.
 
10) Opendro SS, Satoi S, Yanagimoto H, et al : Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy : survival benefit? J Hepotobiliary Pancreat Sci 2014.
PubMed
11) Kobayashi M, Mizuno S, Murata Y, et al : Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma : significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Pancreas 2014 ; 43 : 350-360.
PubMed
12) Murata Y, Mizuno S, Kishiwada M, et al : Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Pancreas 2012 ; 41 : 130-136.
 
13) Murata Y, Hamada T, Kishiwada M, et al : Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepotobiliary Pancreat Sci 2012 ; 19 : 413-425.
 
14) 吉田和弘, 山口和也, 高橋孝夫, ほか : Adjuvant surgeryはstage IV 胃癌, 大腸癌に有用か? 日外科系連会誌 2008 ; 33%8 2008. 12 : 923-924.
 
15) Andriulli A, Festa V, Botteri E, et al : Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer : a meta-analysis of prospective studies. Annals of surgical oncology 2012 ; 19 : 1644-1662.
 
16) Strobel O, Berens V, Hinz U, et al : Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012 ; 152 (3 Suppl 1) : S33-42.
 
17) Hosein PJ, Macintyre J, Kawamura C, et al : A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC cancer 2012 ; 12 : 199.
PubMed
18) Christians KK, Tsai S, Mahrnoud A, et al : Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer : a new treatment paradigm? The oncologist 2014 ; 19 : 266-274.
 
19) Peddi PF, Lubner S, McWilliams R, et al : Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP : JOP 2012 ; 13 : 497-501.
PubMed
20) Mahaseth H, Brutcher E, Kauh J, et al : Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013 ; 42 : 1311-1315.
PubMed
21) Faris JE, Blaszkowsky LS, McDermott S, et al : FOLFIRINOX in locally advanced pancreatic cancer : the Massachusetts General Hospital Cancer Center experience. The oncologist 2013 ; 18 : 543-548.
PubMed
22) Bockhorn M, Burdelski C, Bogoevski D, et al : Arterial en bloc resection for pancreatic carcinoma. The British journal of surgery 2011 ; 98 : 86-92.
PubMed
23) Laurence JM, Tran PD, Morarji K, et al : A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. Journal of gastrointestinal surgery : J Gastrointest Surg 2011 ; 15 : 2059-2069.
PubMed
P.358 掲載の参考文献
1) Satoi S, Yamaue H, Kato K, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobibliary Panceat Sci 2013 ; 20 : 590-600.
PubMed
2) Kato K, Kondo S, Hirano S, et al : Adjuvant surgical therapy for patients with initially unresectable pancreatic cancer with long-term favorable response to chemotherapy. J Hepatobibliary Panceat Sci 2011 ; 18 : 712-716.
PubMed
3) 伊佐地秀司, 岸和田昌之, 村田泰洋, ほか : 局所進行/切除不能膵癌に対する化学放射線療法後の根治切除の意義. 臨外 2012 ; 67 : 66-72.
 
4) 信岡祐, 岸和田昌之, 伊佐地秀司 : 切除不能膵癌に対するdown-sizing chemo (radio) therapyの意義. 臨外 2014 ; 69 : 49-57.
 
5) Bickenbach KA, Gonen M, Tang LH, et al : Downstaging in pancreatic cancer : a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol 2012 ; 19 : 1663-1669.
 
6) Donahue TR, Isacoff WH, Hines OJ, et al : Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors : influence on patient selection for surgery. Arch Surg 2011 ; 146 : 836-843.
PubMed
7) Katz MH, Fleming JB, Bhosale P, et al : Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012 ; 118 : 5749-5756.
 
8) National Comprehensive Cancer Network (NCCN) Practice Guidelines for pancreatic cancer (http://www.nccn.org/clinical.asp)
 
9) 高見秀樹, 藤井努, 神田光郎, ほか : 膵癌の術前化学放射線療法における血管浸潤部の術前画像と病理所見の対比. 胆と膵 2014 ; 35 : 81-86.
Medical*Online
10) Fujiwara Y, Shiba H, Uwagawa T, et al : Curative resection of a primarily unresectable pancreatic cancer after neoadjuvant chemotherapy using Gemcitabine, TS-1, and nafamostat mesilate ; report of a case. Int Surg (in press)
 
11) Egawa S, Toma H, Ohigashi H, et al : Japan Pancreatic Cancer Registry : 30th year anniversary : Japan Pancreas Society. Parlcreas 2012 ; 41 : 985-992.
PubMed
12) Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al : Preoperative/neoadjvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e100267.
 
13) Loehrer PJ Sr, Feng Y, Cardenes H, et al : Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer : an Eastern cooperative Oncology Group trial. J Clin Oncol 2011 ; 29 : 4105-4112.
 
14) Chauffert B, Mornex F, Bonnetain F, et al : Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by rnaintenance gemcitabine alone for locally advancd unresectable pancreatic cancer : definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008 ; 19 : 1592-1599.
 
15) Shinchi H, Takao S, Noma H, et al : Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for localiy unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002 ; 53 : 146-150.
PubMed
16) 日本膵臓学会膵癌診療ガイドライン改訂委員会編 : 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
17) Ueno H, Ioka T, Ikea M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
18) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-1825.
PubMed
19) Von Hoff D, Ervin TJ, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 ; 369 : 1691-1703.
 
20) Arlt A, Gehrz A, Muerkoster S, et al : Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003 ; 22 : 3243-3251.
 
21) Uwagawa T, Li Z, Chang Z, et al : Mechanisms of synthetic serine protease inhibitor (FUT-175) -mediated cell death. Cancer 2007 ; 109 : 2142-2153.
PubMed
22) Uwagawa T, Chiao PJ, Gocho T, et al : Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res 2009 ; 29 : 3173-3178.
PubMed
23) Uwagawa T, Misawa T, Sakamoto T, et al. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol 2009 ; 20 : 239-243.
PubMed
24) Uwagawa T, Misawa T, Tsutsui N, et al : Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Am J Clin Oncol 2013 ; 36 : 44-48.
PubMed
25) Assifi MM, Lu X, Eibl G, et al : Neoadjuvant therapy in pancreatic adenocarcinoma : a meta-analysis of phase II trials. Surgery 2011 ; 150 : 466-473.
PubMed

VII. 放射線療法

P.369 掲載の参考文献
1) (NCCN), N. C. C. N. Pancreatic adenocarcinoma. Practice guidelines in oncology. V. 2013. 2013 ; Available from : http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.
 
2) Gillen S, Schuster T, Meyer Zum Buschenfeide C, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 ; 7 : e1000267.
 
3) Doi R, Imamura M, Hosotani R, et al : Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer : final results of a randomized multi-institutional trial. Surg Today 2008 ; 38 : 1021-1028.
PubMed
4) Satoi S, Yanagimoto H, Toyokawa H, et al : Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009 ; 38 : 282-288.
PubMed
5) Sho M, Akahori T, Tanaka T, et al : Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci 2013 ; 20 : 197-205.
PubMed
6) Takahashi Y, Kaneoka Y, Maeda A, et al : Distal pancreatectomy with celiac axis resection for carcinoma of the body and tail of the pancreas. World J Surg 2011 ; 35 : 2535-2542.
PubMed
7) Willett CG, Safran H, Abrams RA, et al : Clinical research in pancreatic cancer : the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 2003 ; 56 (4 Suppl) ; 31-37.
 
8) Milano MT, Chmura SJ, Garofalo MC, et al : Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies : toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004 ; 59 : 445-453.
PubMed
9) Fuller CD, Dang ND, Wang SJ, et al : Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas : Initial clinical results. Radiother Oncol 2009 ; 92 : 249-254.
PubMed
10) Nakamura A, Shibuya K, Matsuo Y, et al : Analysis of Dosimetric Parameters Associated With Acute Gastrointestinal Toxicity and Upper Gastrointestinal Bleeding in Locally Advanced Pancreatic Cancer Patients Treated With Gemcitabine-Based Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012 ; 84 : 369-375.
PubMed
P.378 掲載の参考文献
1) 膵癌登録報告 2007. 膵臓 2007 ; 22 : e1-427.
 
2) Brunner TB, Scott-Brown M : The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 2010 ; 5 : 64.
 
3) Ohigashi H, Ishikawa O, Eguchi H, et al : Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimentional conformal radiation, surgery and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009 ; 250 : 88-95.
 
4) Evans DB, Varadhachary GR, Crane CH, et al : Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreas head. J Clin Oncol 2008 ; 26 : 3496-3502.
 
5) Talamonti MS, Small W Jr, Mulcahy MF : A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006 ; 13 : 150-158.
PubMed
6) Turrini O, Ychou M, Moureau-Zabotto L, et al : Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas : New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol 2010 ; 36 : 987-992.
PubMed
7) Stokes JB, Nolan NJ, Stelow EB, et al : Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011 ; 18 : 619-627.
PubMed
8) Tachezy M Gebauer F, Petersen C, et al : Sequentiai neoadjuvant chemoradiationtherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma : NEOPA-a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer. 2014 ; 14 : 411.
 
9) Uesaka K, Fukutomi A, Boku N, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2013 ; 31 (suppl) : abst145.
 
10) Eguchi H, Nagano H, Kobayashi S, et al : A phase I trial of combination therapu using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer. Cancer Chemother Pharmacol 2014 ; 73 : 309-315.
 
11) Poppe MM, Narra V, Yue NJ, et al : A comparison of helical intensity-modulated radiationtherapy, intensity-modulated radiotherapy, and 3D-conformal radiation therapy for pancreatic cancer. Med Dosim 2011 ; 36 : 351-357.
 
12) Patel M, Hoffe S, Malafa M, et al : Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 2011 ; 104 : 155-161.
PubMed
13) Yovino S, Maidment BW 3rd, Herman JM, et al : Analysis of local control in patients receiving IMRT for resected pancreatic cancer. Int J Radiat Oncol Biol Rhys 2012 ; 83 : 916-920.
 
14) Fukushima M, Sakamoto K, Sakata M, et al : Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 2010 ; 24 : 1307-1313.
PubMed
15) Lawrence TS, Chang EY, Hahn TM, et al : Delayed radiosensitization of human colon carcinoma cells after brief exposure to 2', 2'-difluoro-2'-deoxycytidine (Gemcitabine). Clin Cancer Res 1997 ; 3 : 777-782.
PubMed
16) Spalding AC, Jee KW, Vineberg K, et al : Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007 ; 34 : 521-529.
PubMed
17) Kavanagh BD, Pan CC, Dawson LA, et al : Radiation dose-volume effects in the stomach and small bowel. Int J Radiation Oncology Biol Phys 2010 ; 76 : S101-107.
 
P.383 掲載の参考文献
1) 大西洋, 唐澤久美子, 唐澤克之編著 : がん・放射線療法 2010. 篠原出版新社, 2010.
 
2) 日本膵癌学会監訳 : NCCN腫瘍学臨床診療ガイドライン 膵腺癌, 2013年 第1版.
 
3) Antoniou G, Kountourakis P, Papadimitriou K, et al : Adjuvant therapy for resectable pancreatic adenocarcinoma : review of the current treatment approaches and future directions. Cancer Treat Rev 2014 ; 40 : 78-85.
PubMed
4) Further evidence of effective adjuvant combined radation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987 ; 59 : 2006-2010.
 
5) Klinkenbijl JH, Jeekel J, Sahmoud T, et al : Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region : phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999 ; 230 : 776-784.
PubMed
6) Neoptolernos JP, Stocken DD, Friess H, et al : A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 ; 350 : 1200-1210.
 
7) Ren F, Xu YC, Wang HX, et al : Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma : continue or stop? Pancreatology 2012 ; 12 : 162-169.
 
8) Moertel CG, Frytak S, Hahn RG, et al : Therapy of locally unresectable pancreatic carcinorna : a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil : The Gastrointestinal Tumor Study Group. Cancer 1981 ; 48 : 1705-1710.
 
9) Treatment of locally unresectable carcinoma of the pancreas : comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988 ; 80 : 751-755.
 
10) Klaassen DJ, Maclntyre JM, Catton GE, et al : Treatment of localiy unresectable cancer of the stomach and pancreas : a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol 1985 ; 3 : 373-378.
 
11) Chauffert B1, Mornex F, Bonnetain F, et al : Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008 ; 19 : 1592-1599.
 
12) Huguet F, Andre T, Hammel P, et al : Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase I and III studies. J Clin Oncol 2007 ; 25 : 326-331.
PubMed
P.391 掲載の参考文献
1) Matsuno S, Egawa S, Fukuyama S, et al : Pancreatic Cancer Registry in Japan : 20 years of experience. Pancreas 2004 ; 28 : 219-230.
PubMed
2) Siegel R, Ma J, Zou Z, et al : Cancer statistics, 2014. CA Cancer J Clin 2014 ; 64 : 9-29.
PubMed
3) Klautke G, Brunner TB : Radiotherapy in pancreatic cancer. Strahlenther Onkol 2008 ; 184 : 557-564.
PubMed
4) Bilimoria KY, Talamonti MS, Sener SF, et al : Effect of hospitai volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008 ; 207 : 510-519.
 
5) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 2013 ; 31 : 1640-1648.
PubMed
6) Moertel CG, Frytak S, Hahn RG, et al : Therapy of locally unresectable pancreatic carcinoma : a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil : The Gastrointestinal Tumor Study Group. Cancer 1981 ; 48 : 1705-1710.
 
7) Loehrer PJ Sr, Feng Y, Cardenes H, et al : Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer : an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011 ; 29 : 4105-4112.
 
8) Pisters PW, Hudec WA, Lee JE, et al : Preoperative chemoradiation for patients with pancreatic cancer : toxicity of endobiliary stents. J Clin Oncol 2000 ; 18 : 860-867.
PubMed
9) Krishnan S, Rana V, Janjan NA, et al : Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007 ; 110 : 47-55.
PubMed
10) Yovino S, Poppe M, Jabbour S, et al : Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011 ; 79 : 158-162.
PubMed
11) Ben-Josef E, Shields AF, Vaishampayan U, et al : Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004 ; 59 : 454-459.
PubMed
12) Murphy JD, Adusumilli S, Griffith KA, et al : Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007 ; 68 : 801-808.
PubMed
13) Nakamura A, Shibuya K, Matsuo Y, et al : Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012 ; 84 : 369-375.
PubMed
14) Ehler ED, Nelms BE, Tome WA : On the dose to a moving target while employing different IMRT delivery mechanisms. Radiother Oncol 2007 ; 83 : 49-56.
PubMed
P.398 掲載の参考文献
1) Oonishi K, Cui X, Hirakawa H, et al : Different effects of carbon ion beams and x-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol 2012 : 105 : 258-265.
 
2) Okada T, Kamada T, Tsuji H, et al : Carbon ion radiotherapy : Clinical experiences at national institute of radiological science (nirs). J Radiat Res 2010 ; 51 : 355-364.
PubMed
3) Shinoto M, Yamada S, Yasuda S, et al : Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 2013 ; 119 : 45-51.
PubMed
4) Ikeda M, Okada S, Tokuuye K, et al : A phase i trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002 ; 86 : 1551-1554.
PubMed
5) Murphy JD, Adusumilli S, Griffith KA, et al : Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007 ; 68 : 801-808.
PubMed
6) Sudo K, Yamaguchi T, Ishihara T, et al : Phase ii study of oral s-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011 ; 80 : 119-125.
 
7) Koong AC, Mehta VK, Le QT, et al : Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000 ; 48 : 919-922.
PubMed
8) Antonovic L, Lindblom E, Dasu A, et al : Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy : The influence of local oxygenation changes. J Radiat Res 2014.
PubMed
9) Chang DT, Schellenberg D, Shen J, et al : Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009 ; 115 : 665-672.
PubMed
10) Bai YR, Wu GH, Guo WJ, et al : Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer : Results of feasibility study. World J Gastroenterol 2003 ; 9 : 2561-2564.
PubMed
11) Shinoto M, Yamada S, Yoshikawa K, et al : Usefulness of 18f-fluorodeoxyglucose positron emission tomography as predictor of distant metastasis in preoperative carbon-ion radiotherapy for pancreatic cancer. Anticancer research 2013 ; 33 : 5579-5584.
PubMed

VIII. 興味ある症例

P.404 掲載の参考文献
1) 牧野裕庸, 亀高尚, 小山隆史, ほか : 切除不能進行膵癌に対してS-1を中心とした集学的治療により長期生存中の1例. 癌と化療 2011 ; 38 : 2647-2650.
Medical*Online
2) 久慈麻里子, 山本康弘, 谷誓良, ほか : Gerncitabine併用療法が奏功した切除不能膵癌の1例. 癌と化療 2011 ; 38 : 853-855.
 
3) 岩佐悟, 上野秀樹, 奥坂拓志, ほか : がん化学療法の実際 膵癌 切除不能膵癌の化学療法. 外科治療 2008 ; 98 : 638-646.
 
4) 澤田成朗, 吉岡伊作, 黒木壽人, ほか : 腹膜播種を伴う進行膵体尾部癌に対しS-1+GEM療法後, RO手術が可能であった一例. 膵臓 2011 ; 26 : 524-530.
 
5) 木村寛伸, 伏田幸夫, 武川昭男 : S-1/Gemcitabine, Paclitaxel併用療法が奏功し根治切除が可能となった腹膜播種を伴う膵体部癌の1例. 癌と化療 2009 ; 36 : 1191-1194.
 
6) 新地洋之, 高尾尊身, 前川公成, ほか : Gemcitabine療法が奏功し根治切除が可能となった腹膜播種を伴う膵尾部癌の1例. 癌と化療 2007 ; 34 : 773-776.
 
7) 日本膵臓学会編, 膵癌取扱い規約 (第6版). 金原出版, 2009 ; 27-31.
 
8) 田中雅夫 : 膵癌登録報告 2007. 膵臓 2007 ; 22 : e26-e28.
 
9) 相浦浩一, 高橋伸, 上田政和, ほか : 膵癌術後長期生存例における剖検4例の検討. 膵臓 2007 ; 22 : 130-136.
Medical*Online
10) 上野誠, 大川伸一 : 膵癌の予後予測におけるFDG-PETの有用性. 胆と膵 2012 ; 33 : 417-419.
Medical*Online
P.409 掲載の参考文献
1) 松野正紀, 伊佐治秀司, 今泉俊秀, ほか : 日本膵臓学会膵癌登録20年間の総括. 膵臓 2003 ; 18 : 101-169.
 
2) 島田和明, 岸庸二, 奈良聡, ほか : 膵粘液癌-まれな膵癌分泌腫瘍. 胆と膵 2012 ; 33 : 685-690.
 
3) NCCN org : NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) version 1, 2013. Pancreatic Adenocarcinoma
 
4) Sudo K, Yamaguchi T, Ishihara T, et al : Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011 ; 80 : 119-125.
 
5) 日本膵臓学会膵癌診療ガイドライン改定委員会編, 科学的根拠に基づく膵癌診療ガイドライン 2013年版. 金原出版, 2013.
 
P.413 掲載の参考文献
1) 日本膵臓学会編, 膵癌取扱い規約 (第6版). 金原出版, 2009.
 
2) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 2007 ; 22 : 718-720.
 
3) Wisnoski NC, Townsend CM Jr, Nealon WH, et al : 672 patients with acinar cell carcinoma of the pancreas : a population-based comparison to pancreatic adenocarcinoma. Surgery 2008 ; 14 : 141-148.
 
4) Kitagami H, Kondo S, Hirano S, et al : Acinar cell carcinoma of the pancreas : clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas 2007 ; 35 : 42-46.
PubMed
5) Chiou YY, Chiang JH, Hwang JI, et al : Acinar cell carcinoma of the pancreas : clinical and computed tomography manifestations. J Comput Assist Tomogr 2004 ; 2 : 180-186.
PubMed
6) Suzuki A, Sakaguchi T, Morita Y, et al : Long-term survival after a repetitive surgical approach in a patient with acinar cell carcinoma of the pancreas and recurrent liver metastases : report of a case. Surg Today 2010 ; 40 : 679-683.
 
7) 森嶋計, 俵藤正信, 仁平芳人, ほか : S-1が奏効した膵腺房細胞癌多発肝転移の1例. 癌と化療 2010 ; 37 : 127-129.
Medical*Online
P.417 掲載の参考文献
1) Tsujii H, Kamada T : A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol 2012 ; 42 : 670-685.
PubMed
2) 出水祐介, 不破信和 : 粒子線治療 (Particle therapy). 肝胆膵 2013 ; 67 : 195-202.
Medical*Online
3) Shinoto M, Yamada S, Yasuda S, et al : Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 2013 ; 119 : 45-51.
PubMed
4) Okada T, Kamada T, Tsuji H, et al : Carbon ion radiotherapy : clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res 2010 ; 51 : 355-364.
PubMed
5) 伊藤博, 木村文夫, 清水宏明, ほか : 重粒子線術前照射併用膵癌切除症例の経験. 癌と化療 2004 ; 31 : 1879-1881.
Medical*Online
6) Ikeda M, Okada S, Tokuuye K, et al : A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002 ; 86 : 1551-1554.
PubMed
7) 篠藤誠, 塩山善之 : 新しい炭素線治療. 映像情報 Medical 2013 ; 45 : 867-871.
Medical*Online
8) El Shafie RA, Habermehl D, Rieken S, et al : In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. J Radiat Res 2013 ; 54 : i113-119.
PubMed
9) Oonishi K, Cui X, Hirakawa H, et al : Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol 2012 ; 105 : 258-265.
 
10) 崔星, 若井俊文, 趙建東, ほか : 重粒子単独或はGemcitabine併用によるヒト膵癌幹細胞及び移植腫瘍抑制効果. 膵臓 2013 ; 28 : 417.
 
P.421 掲載の参考文献
1) http://www.tri-kobe.org/nccn/guideline/pancreas/japanese/pancreaticpdf
 
2) Stokes JB, Nolan NJ, Stelow EB, et al : Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011 ; 18 : 619-627.
PubMed
3) Evans DB, Varadhachary GR, Crane CH, et al : Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma for the pancreatic head. J Clin Oncol 2008 ; 26 : 3496-3502.
 
4) Ohigashi H, Ishikawa O, Eguchi H, et al : Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dirnensional conformal radiation, surgery, and postoperative liver perfusion chemoradiation for T3-pancreatic cancer. Ann Surg 2009 ; 250 : 88-95.
PubMed
5) Turrini O, Ychou M, Moureau-Zabotto L, et al : Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas : New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol 2010 ; 35 : 987-992.
 

書評

最近チェックした商品履歴

Loading...